

Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

ARTICLE

Evaluation of a Focused Virtual Library of Heterobifunctional Ligands for *Clostridium difficile* Toxins

Cite this: DOI: 10.1039/x0xx00000x

Received 00th January 2012,
Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

Carlos A. Sanhueza,^a Jonathan Cartmell,^a Amr El-Hawiet,^a Adam Szpacenko,^a Elena N. Kitova,^a Rambod Daneshfar,^a John S. Klassen,^a Dean E. Lang,^b Luiz Eugenio,^b Kenneth K.-S. Ng,^b Pavel I. Kitov^a and David R. Bundle^{a*}

A focused library of virtual heterobifunctional ligands was generated *in silico* and a set of ligands with recombined fragments was synthesized and evaluated for binding to *Clostridium difficile* toxins. The position of the trisaccharide fragment was used as a reference for filtering docked poses during virtual screening to match the trisaccharide ligand in a crystal structure. The peptoid, a diversity fragment probing the protein surface area adjacent to a known binding site, was generated by a multi-component Ugi reaction. Our approach combines modular fragment-based design with *in silico* screening of synthetically feasible compounds and lays the groundwork for future efforts in development of composite bifunctional ligands for large clostridial toxins.

Introduction

Clostridium difficile is a Gram-positive anaerobic bacterium that often colonizes the gut of mammals. In humans, this organism is the causative agent of *Clostridium difficile* infection (CDI).^{1, 2} CDI imposes increasing burden on health care systems in industrialized countries often requiring patient isolation and, in extreme cases, resulting in hospital closures. The annual cost of hospital care for patients with CDI was estimated at \$3.2 billion in the US.³ Although CDI is primarily a nosocomial infection other recent reports of livestock harboring pathogenic strains of *C. difficile* also suggest a food-borne link.⁴⁻⁶

CDI manifests itself in symptoms ranging from mild diarrhea to life threatening pseudomembranous colitis that can lead to death in elderly and immuno-compromised patients. Growing resistance to antibiotics leaves few options for treatment other than the administration of either metronidazole or vancomycin.⁷ However, due to the ability of the bacterium to form endospores, the treatment with broad spectrum antibiotics is often inefficient since the suppression of regular intestinal microflora provides a competitive advantage to *C. difficile*, which often results in high recurrence rate (up to 20% of patients).² Recently approved Fidaxomicin, a narrow scope antibiotic, causes less collateral damage to microflora and is indicated to high risk patients.⁸

Pathogenic strains of *C. difficile* express at least two UDP-glucosylating toxins A and B (TcdA and TcdB), and, in 6% of strains, also ADP-ribosylating binary toxin, which may increase severity but is unlikely to cause the disease in the absence of large clostridial toxins TcdA and TcdB.⁹ In contrast to TcdA and TcdB, the binary toxin does not have an internal cysteine protease domain and relies on trypsin for its activation. The cell surface receptor for TcdA and TcdB was identified in rodents as Gal(α1-3)Gal(β1-4)GlcNAc(β1-O) trisaccharide

(αGalLacNAc).¹⁰ This glycan sequence, also known as "Galili antigen"¹¹ for its role in xenotransplantation organ rejection, is found on the cell membrane of rabbit erythrocytes and other tissues in mammals but not in humans. Several oligosaccharide structures found in human milk¹² or decorating the surface of human epithelial cells^{13, 14} have been reported to bind clostridial toxins with weak affinities similar to that of the Galili antigen. The high potency of the toxins is attributed to multivalency-enhanced avidity due to simultaneous interaction of multiple carbohydrate-recognition domains located at the C-terminus with the host cell surface.^{15, 16} Binding of the C-terminus initiates ligand-mediated endocytosis followed by auto-catalytic cleavage of the enzyme domain, which is translocated to the cytosol and glucosylates target proteins.¹⁷ Clostridial toxins covalently modify large number of proteins¹⁷ including Rho GTPases causing their functional inactivation and inducing disassembly of the actin cytoskeleton, which in turn leads to morphological changes and death of susceptible cells, and, ultimately, results in erosion and perforation of the intestinal epithelium.^{15, 18}

Considering the emergence of more virulent strains and resistance to antibiotics,^{19, 20} for opportunistic pathogens such as *Clostridia*, nonlethal anti-infection therapies are required that target virulence factors rather than suppress bacterial growth. Passive immunotherapy²¹ and manipulation of the human microbiome by repopulating intestine with non-toxigenic strain of *C. difficile*²² are new approaches in managing CDI. Large clostridial toxins TcdA and TcdB also appear an attractive therapeutic target for development of both antibodies and chemical antidotes. A non-specific affinity agent, polystyrene-based sulfonate polymer Tolevamer that passively absorbs and neutralizes CD toxins in the gut is considered a proof-of-principle for such an approach. Although it has been shown to have lower efficacy than broad range antibiotics in clinical trials, treatment with Tolevamer led to dramatically reduced

recurrence of CDI.²³ Inhibitors of the glucosyltransferase²⁴ and autocatalytic protease domain in TcdB have recently been reported.²⁵

The crystal structure of TcdA-A2 fragment in a complex with Gal(α 1-3)Gal(β 1-4)GlcNAc(β 1-O)²⁶ (pdb code: 2G7C) provides a structural basis for the rational design of potential inhibitors. Inspection of the structure reveals a shallow groove located near the reducing terminus of the bound trisaccharide. The close proximity of this groove suggests an opportunity for design of heterobifunctional ligands, in which a variable fragment is linked to the trisaccharide via a short spacer (Fig. 1). Here we present a fragment-based strategy for developing ligands for clostridial toxins TcdA and TcdB, which interrogate a putative supplementary binding site on the protein surface adjacent to the known carbohydrate-binding site.




Fig. 1 Design of heterobifunctional ligands for TcdA. Invariant fragment (IF) is presumed to occupy the same position as Gal(α 1-3)Gal(β 1-4)GlcNAc(β 1-O)(CH₂)₈COOMe trisaccharide in the crystal structure while the variable fragment (VF) enhances binding through supplementary interactions with the putative binding site.

Results

Design of ligands and virtual screening of a combinatorial library

Our approach combines fragment-based design and virtual screening of a combinatorial library. Trisaccharide Gal(α 1-3)Gal(β 1-4)Glc(β 1-O) was chosen as an invariant fragment (IF) of the focused combinatorial library, while the structures of the variable fragment (VF) were suggested by computational screening of virtual combinatorial libraries of pseudo-dipeptides.

To avoid uncertainty in stereo configuration of products we decided to vary only two components, the carboxylic acid and amine in construction of a virtual library of Ugi products and limit the third component to formaldehyde. Lists of fragments R1 and R2 were compiled from structures available from the Aldrich catalogue. Approximately 500 low molecular weight fragments of each type were chosen. Combinatorial library of 3D structures was generated with in-house scripts using Open Babel software.²⁷ During preparation of the structures for docking appropriate positional constraints were used to prevent distortions in carbohydrate portion of the virtual ligands. Of the total library (~250000 structures), approximately 20% representative randomly chosen structures were processed with Autodock Vina.²⁸ Due to the large number of rotatable bonds multiple docking sessions were required for the majority of compounds to obtain poses with low RMSD with respect to the trisaccharide moiety found in the crystal structure. The resulting poses with RMSD less than 1.5 Å were sorted by Vina score and six hits containing different fragments were selected (Fig. 2). The fragments were recombined providing 36 structures for synthesis and activity evaluation.

Synthesis of the ligands

For the preparation of the majority of the ligands Ugi condensation preceded the enzymatic step, while the remaining ligands were obtained *via* a route where the α -Gal moiety was introduced prior to formation of Ugi product. The former approach is more robust and convenient if an individual derivative is a target, while the latter is convergent and more suitable for preparation of a larger series of compounds provided the respective isocyanide derivative is readily available. The assembly of the Gal(α 1-3)Gal(β 1-4)Glc(β 1-O) trisaccharide fragment was accomplished by enzymatic treatment of the corresponding lactose derivative with UDP-glucose in the presence of a fusion protein containing the enzymic activity (α 1-3)-galactosyl transferase,²⁹ and UDP-GalNAc(Gal)/GlcNAc(Glc) epimerase.³⁰

The synthesis started with the installation of the linker moiety into the oligosaccharide structure by boron trifluoride-catalyzed glycosylation of 2-(2-azidoethoxy)ethanol with lactose octaacetate **1** (Scheme 1). Deacetylation of the resulting azido-lactoside **2** and subsequent enzymatic processing followed by acetylation led to trisaccharide glycoside **3**. Conversion of azido derivatives **2** and **3** to the corresponding isocyanides **6** and **7** was accomplished by a one-pot procedure including reduction, *N*-formylation and, finally, dehydration of the *N*-formate (Scheme 1). Although reduction of azide during the first step is coupled to *in situ* catalytic oxidation of formic acid³¹ we found that using a hydrogen atmosphere facilitates the conversion and improves the overall yield.

Condensation of lactosyl isocyanide **6** with variable components, amines and carboxylic acids, in the presence of formaldehyde provided 27 Ugi products as shown in Scheme 1. One carboxylic acid, C6, failed to give the target products, presumably, due to the high reactivity of the pyrazolone ring, which represents a cyclic Schiff-type base and may also undergo condensations with isocyanides. However, its amine counterpart N6 was utilized in the synthesis of the combinatorial products. The subsequent deacetylation and enzymatic treatment of lactosyl derivatives afforded the final products in up to 80% yield (Scheme 1). The remaining 3 derivatives of this series, U_{N1C1}, U_{N4C4} and U_{N6C5}, were obtained *via* the trisaccharide isocyanide **7** (Scheme 1).

Conformational behaviour of glycopeptoids

Substitution at the amide nitrogen in the peptoid moiety of Ugi derivatives changed the preferred conformation and may affect recognition of ligands in biological systems. Due to additional steric interactions the restricted rotation about amide bond is less pronounced for peptoids resulting in a more complex potential energy landscape than for regular peptides.³² The amide bond readily undergoes transition at room temperature, therefore, the more thermodynamically stable configuration prevails. The energy barriers for transition between the two major conformations, *cis* and *trans*, are reduced in peptoids compared to peptides as was shown experimentally and by *ab initio* calculations for *N*-methyl and *N,N*-dimethyl formamides and acetamides.³³ NMR spectra of all Ugi derivatives synthesized in this work, which contained aromatic substituents at the nitrogen atom (N1, N3, N4 and N6), have a single series of signals corresponding to the *trans* conformation of the terminal amide bond. In our set of compounds, most NMR spectra in D₂O presented two series of signals corresponding to *trans*- and *cis*-configurations of the terminal peptidoid bond. The ratios varied depending on whether an aliphatic or aromatic

substituent was present at the amide nitrogen atom. All compounds containing aromatic substituents at the nitrogen atom showed an approximate 20:1 ratio between major (*trans*)

and minor (*cis*) conformers, whereas, the presence of an aliphatic substituent increased the relative





Figure 2. Structures of the original virtual hits and variable components, amines and carboxylic acids, chosen for Ugi condensation. Carboxylic acid C6 (shown in dashed frame) failed to form a product in the Ugi reaction.




abundance of the *cis* component up to 40%. Assignment of conformers was conducted for the representative compound UN1C2 by comparing inter-nuclear Rotating Frame Enhancement

(ROE) cross-peak intensities (volume integrals) with estimated ROE effects based on Molecular Dynamics (MD) trajectories.

Our observations for *N*-aromatic amides are consistent with the previously reported trend in the conformational preferences

for *N*-aryl substituted peptoids and *ab initio* calculations for substituted *N*-methylacetanilides.³⁴ The observed NOE pattern for compound U_{N1C2} matches that obtained by MD simulation at 300 K for the *trans* conformer using the Amber force field (Table 1, Figure 4). More bulky aliphatic substituents (N2 and N5) caused the corresponding Ugi derivatives to exist in both conformations. Up to 40% of the *cis* conformers were observed in the corresponding NMR spectra. This effect should be considered in virtual screening of peptoid structures and highly populated *cis* conformers should be tested for compounds containing amide bonds with aliphatic substituents at the amide nitrogen.

Table 1. Comparison of experimentally observed internuclear Rotating Frame Enhancement (ROE) cross-peak intensities (volume integrals) and estimated ROE effects based on MD trajectories of U_{N1C2} collected over 1 ns in explicit-water run at 300 K.



Through-space contacts	Observed relative volumes, (%)	Calculated for TRANS-conformer (%)	Calculated for CIS-conformer (%)
H-1(Glc)—H-5(Glc) ^[a]	100	100	100
Ha-Hb	21.6	33.0	3.7
Ha-Hc	20.3	32.4	3.6
Ha-Hd	2.2	3.2	0.32

[a] The distance between these protons was used as internal standard (assumed 100%).

Evaluation of binding affinity

The affinities of the ligands were measured by direct electrospray ionization mass spectroscopy (ESI-MS) binding assay³⁵ using relative abundance of ions corresponding to various bound states of the protein-receptor in the presence of a ligand as illustrated in Fig. 3. For example, Fig. 3a shows a representative ESI mass spectrum acquired for a solution of TcdA-A2 (50 μ M), lysozyme (7 μ M) and U_{N5C2} at 50 μ M in aqueous ammonium acetate buffer (10 mM). Lysozyme served as P_{ref} for the binding measurements performed on TcdA-A2. Inspection of the ESI mass spectrum reveals signals corresponding to protonated ions of free (unbound) A2 fragment as well as the A2 bound to one, two and three molecules of U_{N5C2} , i.e. $(TcdA-A2^+qU_{N5C2})^{n+}$, where $q=0-3$ and $n=9-11$. Ions corresponding to unbound and bound P_{ref} ions were also detected i.e. $(P_{ref}^+qU_{N5C2})^{n+}$, where $q=0-2$ and $n=8, 7$ indicating that nonspecific binding of U_{N5C2} to TcdA-A2 occurred during the ESI process and contributed to the mass spectrum.




Figure 3. (a) ESI mass spectra of aqueous solutions containing 75 μ M TcdA-A2, 100 μ M U_{N5C2} at pH 7 and 25°C. A P_{ref} (10 μ M) was added to quantify the extent of nonspecific protein-ligand binding during the ES process. (b) ESI mass spectra of aqueous solutions containing 15 μ M B3, 50 μ M U_{N4C4} at pH 7 and 25°C. A P_{ref} (10 μ M) was added to quantify the extent of nonspecific protein-ligand binding during the ES process.

Listed in Table 2 are the results of the ESI-MS binding measurements performed on the thirty compounds. Where binding was detected, the affinities were determined based on at least six measurements performed at multiple ligand concentrations. In all cases, the ESI mass spectra were corrected for nonspecific binding using the reference protein method.³⁶ Low affinities have prevented an accurate measurement of the affinity for a number of ligands. For the purpose of data analysis, apparent binding constants for these ligands were assigned the value of 500 M^{-1} as was previously determined for the reference trisaccharide, Gal(α 1-3)Gal(β 1-4)GlcNAc(β 1-O(CH₂)₈COOMe).¹¹

Crystal structure of TcdA bound to U_{N5C2}

To further define the mode of binding predicted for the glycopeptoid ligands, a crystal structure was determined for a complex between a fragment of TcdA (TcdA-A2) containing two carbohydrate-binding sites and one of the ligands (U_{N5C2}) with significant binding affinity to both TcdA and TcdB. The

crystal structure was determined to 1.7 Å resolution and reveals a mode of binding for the trisaccharide that is essentially identical to that seen previously in the complex of the same fragment of TcdA2 bound to free trisaccharide (2G7C).²⁶ Although the peptoid aglycone increases binding affinity slightly compared to the reference trisaccharide, most of the aglycone does not appear to adopt a single, well-ordered structure, as the electron density map in the region expected for the aglycone is quite weak and not readily interpretable (Fig. 5). Because two copies of the protein, each containing two carbohydrate-binding sites, are present in the asymmetric unit of this crystal form, four independent carbohydrate-binding sites are visible in the asymmetric unit of this crystal (same crystal form previously reported for 2G7C).

Table 2. Apparent association constants, $K_{a,app}$ (units of M^{-1}) for binding of the Trisaccharide-Ugi derivatives with TcdA-A2 and TcdB-B3C fragments determined at 25°C and pH 7 by the direct ESI-MS assay.

compound	apparent affinity to TcdA-A2	apparent affinity to TcdB-B3C
Gal(α1-3)Gal(β1-4)GlcNAc(β1-O(CH ₂) ₈ COOMe)	500 ¹¹	
U _{N1C1}	NB ^[a]	6500 ± 200
U _{N1C2}	3000 ± 600	9400 ± 1300
U _{N1C3}	NB.	8300 ± 1700
U _{N1C4}	1800 ± 400	6300 ± 400
U _{N1C5}	NB	5700 ± 300
U _{N2C1}	NB	6000 ± 300
U _{N2C2}	NB	5800 ± 500
U _{N2C3}	900 ± 200	5000 ± 800
U _{N2C4}	3100 ± 400	6500 ± 200
U _{N2C5}	NB	6700 ± 1200
U _{N3C1}	NB	3900 ± 400
U _{N3C2}	900 ± 300	4900 ± 800
U _{N3C3}	NB	5600 ± 200
U _{N3C4}	1800 ± 200	8700 ± 300
U _{N3C5}	NB	6800 ± 600
U _{N4C1}	NB	7500 ± 800
U _{N4C2}	NB	4100 ± 200
U _{N4C3}	NB	5600 ± 700
U _{N4C4}	300 ± 200	5700 ± 600
U _{N4C5}	NB	4100 ± 700
U _{N5C1}	2300 ± 300	11300 ± 300
U _{N5C2}	2600 ± 200	7000 ± 400
U _{N5C3}	1800 ± 300	11000 ± 600
U _{N5C4}	2200 ± 300	11000 ± 500
U _{N5C5}	1300 ± 400	10100 ± 800
U _{N6C1}	NB	6000 ± 600
U _{N6C2}	2300 ± 600	7300 ± 800
U _{N6C3}	NB	7500 ± 100
U _{N6C4}	2300 ± 500	7000 ± 500
U _{N6C5}	NB	5700 ± 300

[a] No Binding indicates low affinity and large error, not necessary complete absence of the complex in the spectrum.

The electron density for only one of the four sites is shown in Fig. 5, but the electron density in the region expected for the aglycone in the other three sites is equally weak and uninterpretable, even though the electron density for the trisaccharide is quite strong in all sites. The lack of clear electron density for most of the aglycone suggests the presence of a significant amount of flexibility in the linker and the lack of a well-defined, single mode of binding. These observations are consistent with the results from NMR and molecular dynamics simulations described above, which confirm the

flexibility of the linker and indicate that a fairly wide range of conformations can be adopted by the aglycone.




Fig. 4. Mapping of binding sites of large clostridial toxins. The residues contacting the carbohydrate ligand are highlighted in red. Peripheral groove area, the putative supplementary binding site, is highlighted in green. Lower: Amino acid sequence alignment of TcdA binding sites in fragment (pdb code: 2G7C). Sequence consistency index (CI) was calculated for strain 630 and includes 7 homologous sites in TcdA and 4 sites in TcdB. Symbol (*) designates highest rank of 10.




Fig. 5. Crystal structure of TcdA-A2 bound to U_{N5C2}. The trisaccharide and a short, partially ordered segment of the aglycone (carbon atoms colored green and oxygen atoms colored red) is modeled to fit the electron density at one of the four carbohydrate-binding sites in the asymmetric unit. This binding site seems most open and free from adjacent molecules in the crystal lattice, but very similar electron density for the trisaccharide and aglycone is seen at all four binding sites. Difference electron density maps are contoured at 2.8σ (red) and 2.0σ (blue), where σ = standard deviation above the mean. The refined structure of the trisaccharide is shown, but the coordinates were removed prior to the last round of refinement and map calculation to reduce model bias. The region where the aglycone is expected to interact with the protein is marked with a dashed black line. The solvent-accessible surface of the protein is drawn in a semi-transparent representation superimposed onto a stick representation.

Discussion

The four-component Ugi reaction offers convenient access to highly diverse compound libraries. Synthetically, the condensation is robust and relatively independent of the nature of reactants and, thus, particularly suitable for the initial stage of a ligand discovery program, which relies on diversity-oriented virtual screening.

The presence of multiple carbohydrate binding sites with homologous but not quite identical sequences of the repeats adds complexity to structure-based design of inhibitors for large

clostridial toxins. Sequence alignment suggests the presence of 7 putative carbohydrate binding domains (CBDs) in TcdA and 4 CBDs in TcdB. Side chains of amino acids that form the binding sites differ significantly from site to site, and from strain to strain. This variation is even more significant between the binding sites found in TcdA versus TcdB. Polar side chains can be replaced with aromatic or hydrophobic ones, and charged side chains can be replaced with those carrying the opposite charge. The remarkable ability to maintain such diversity without loss of function may be beneficial for the bacteria for both evading the immune system and targeting a wide range of cell-surface receptors, but this significant degree of variation presents a formidable challenge for development of efficient antagonists for the receptor-binding domain of the large clostridial toxins.

The area on the protein surface that spans approximately 20 Å in diameter and can be accessed from the reducing terminal of the bound trisaccharide in the crystal structure 2G7C contains a groove composed of a relatively more conserved set of amino acids (Fig. 4, green highlighting). From a pharmacological prospective, targeting the relatively conserved region outside the native binding site appears to be an attractive strategy. Interaction with this supplementary site may be more uniform than with the highly variable principal binding site.

Even though only a short linker is required to bridge the trisaccharide and the putative ligand in this groove, the resulting structures of heterobifunctional composite ligands are very flexible with approximately 20 rotatable bonds (~30 if OH groups are included). Docking of such structures presents a considerable challenge; selection of the docked poses cannot be guided solely by a scoring function and additional information about conformational preferences of the structural elements has to be considered. For instance, the conformational behaviour of oligosaccharides is governed by the exo-anomeric effect³⁷ as is apparent from thousands of available glycan crystal structures and NMR studies.³⁸ In this work, we reduced the conformational search during the automated docking by restraining all internal degrees of freedom in the trisaccharide fragment. Additionally, the pose of the trisaccharide in crystal structure 2G7C was used as a reference for selection of plausible docked poses. Applying these constraints should permit evaluation of possible contributions by the auxiliary binding site assuming the carbohydrate fragment binds consistently.

Exhaustive computational evaluation of the entire combinatorial library may be hindered due to large computational expense while sampling of a fraction of the library may still permit identification of promising fragments. We tested this by recombining the fragments found in a small subset of original virtual hits and evaluating activities of these recombinant compounds. Out of five synthesized ligands that were originally identified by virtual screening against TcdA-A2, only one (U_{N5C5}) has shown greater affinity than the reference trisaccharide while recombination of the Ugi reaction components gave significantly better results with more than one third of recombinant ligands showing higher activity than the reference trisaccharide (Table 1). Interestingly, all derivatives containing an amine fragment N5 were active when combined with any tested carboxylic acid fragment and against both TcdA and TcdB. Some fragments produce more active Ugi derivatives than the others, however, no synergy was observed and combination of “active” amines with “active” carboxylic acid did not produce a compound with outstanding activity.

Conclusions

To interrogate a supplementary binding site on the surface of large clostridial toxins a library of virtual molecules composed of a trisaccharide as an invariant fragment and a dipeptoid as a variable moiety was evaluated by docking. A set of 30 rearranged structures was synthesized and their binding activities with respect to two *Clostridium difficile* toxins, TcdA and TcdB, were measured by mass spectrometry. A number of ligands were found to bind better than the original trisaccharide to both *C. difficile* toxins thereby validating the underlying design approach, in which additional fragment targeting of a supplementary binding site enhances overall affinity.

Experimental Section

General methods

Commercially available reagents were used as supplied without further purification. Evaporation and concentration *in vacuo* was conducted under water-aspirator pressure. Reactions that required anhydrous conditions were carried out in argon atmosphere. Reactions were monitored by analytical thin-layer chromatography (TLC) with pre-coated silica gel 60 F₂₅₄ glass plate (Merck). Plates were visualized under UV light or stained by treatment with cerium ammonium molybdate solution or 5% sulfuric acid in ethanol followed by heating at 180 °C. Amine containing compounds were visualized by treatment with 1% ninhydrin solution in ethanol followed by heating at 180 °C. Purification of products was conducted by column chromatography using silica gel SiliaFlashF60 (40-63 µm, 60 Å) from SiliCycle® Inc. Purification of deprotected final products was conducted by HPLC on reverse-phase C-18 column using water-acetonitrile gradient as eluent. NMR spectra were recorded at 500 or 600 MHz, at 27 °C in CDCl₃ or D₂O. Coupling constants are first order and chemical shifts are referenced to residual solvent (CDCl₃) at 7.24 p.p.m. for ¹H and 77.0 p.p.m. for ¹³C-spectra and relative to 0.1% external acetone at 2.225 ppm for ¹H-spectra in D₂O. IR data were recorded on Nic-Plan IR Microscope (solid film); only signals corresponding to indicative functional groups are reported. Electrospray ionization high resolution mass spectra (ESI-HRMS) were recorded on a Micromass Zabspec TOF-mass spectrometer.

Azide reduction. Reduction of an azide group was performed at room temperature by hydrogenation in ethyl acetate (10 mL/mmol) using Pd/C 10% (50 mg/mmol) as catalyst. Once the reduction was complete (TLC), catalyst was removed by filtration through a bed of Celite® and the filtrate was concentrated.

Synthesis of *N*-formamide. To a solution of the amine derivative in ethyl acetate Et₃N (2.0 eq.) was added followed by freshly prepared mixed anhydride of acetic and formic acids (10.0 eq.).³⁶ After 20 min of stirring at room temperature the system was concentrated under vacuum and the resulting crude product was redissolved in DCM and washed with saturated solution of NaHCO₃. The organic layer was separated, dried over Na₂SO₄, concentrated and the residue was purified by flash column chromatography on silica gel with ethyl acetate-hexanes mixtures as eluent.

Synthesis of isocyanides. POCl₃ (1.0 eq.) was added by syringe to a solution of saccharide derived *N*-formamide and Et₃N (10 eq.) in dry DCM (1.0 mL/mmol) at 0 °C under argon atmosphere. The mixture was allowed to warm to room temperature and kept until total consumption of the starting

material (usually in less than 15 min) as monitored by TLC. Solvent was removed in vacuum and the crude product was purified by flash chromatography on silica gel using ethyl acetate-hexanes (supplemented by 2 % Et₃N) as eluent.

General method for Ugi condensation. A solution of amine (1.0 eq.), paraformaldehyde (1.0 eq.), carboxylic acid (1.0 eq.) and the sugar-derived isocyanide in methanol was stirred at 60 °C overnight. Then methanol was removed in vacuum and the residue was filtered through a silica gel pack for crude purification. Deprotection of acetyl groups was effected by Zemplen trans-esterification. The lactose derivatives were processed further by enzymatic glycosylation reaction. The final trisaccharides derivatives were purified by HPLC on C-18 reverse phase using water-acetonitrile solutions as eluent.

Enzymatic reaction. Bovine alkaline phosphatase (Sigma) was used as supplied. (α-1-3)-Galactosyl transferase (E.C. 2.4.1.87)³⁹ from calf thymus and UDP-glucose 4-epimerase⁴⁰ from *Campylobacter jejuni* were expressed in *Escherichia coli* and used without purification as cell lysates (1 g pellet gives 4.5 mL lysate). To a solution of lactose substrate (0.2 mmol) in HEPES buffer (1.4 mL, 0.2 M, 1.25 mM MnCl₂, 1% BSA, pH 8.0) the enzymes and reagents were added in the following order: epimerase (0.7 mL), transferase (1.3 mL), phosphatase (9 μL), UDP-glucose (1.2-1.5 eq.). The mixture was incubated for 1-3 days at 37 °C while the progress was monitored by TLC. The reaction was stopped by addition of acetic acid (175 μL), the mixture was centrifuged at 7000 rpm for 20 min and the supernatant was freeze-dried. When acetylation of the product was required prior to purification the residue was suspended in a pyridine-acetic anhydride mixture (1:1, 2 mL) and stirred for 5 h; then MeOH (1 mL) was added. The mixture was concentrated in vacuum and the residue was chromatographed on silica gel.

2-(2-Formamidoethoxy)ethyl 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glycopyranoside

(4). Reduction and subsequent *N*-formylation of lactose-derived azide **2** (2.84 g, 3.79 mmol)⁴¹ was achieved according to the general procedure for formamide synthesis to give compound **4** (1.82 g, 2.42 mmol, 64%) as a colorless solid, *R_f* 0.38 (DCM/MeOH, 19:1), [α]_D -13.4 (*c* 1.3, CHCl₃); IR (cm⁻¹): 3389, 2941, 2877, 1753, 1237; ¹H NMR (CDCl₃, 600 MHz), δ (ppm): 8.22 (s, 1H, NHCHO), 6.25 (s, 1H, NHCHO), 5.35 (dd, 1H, *J*_{4,3} 1.0, *J*_{4,5} 3.6 Hz, H-4'), 5.22 (dd, 1H, *J*_{3,2} ≈ *J*_{3,4} 9.0 Hz, H-3), 5.11 (dd, 1H, *J*_{2,1} 7.8, *J*_{2,3} 10.2 Hz, H-2'), 4.96 (dd, 1H, *J*_{3,4} 3.6, *J*_{3,2} 10.5 Hz, H-3'), 4.90 (dd, 1H, *J*_{2,1} 7.8, *J*_{2,3} 9.6 Hz, H-2), 4.55 (d, 1H, *J*_{1,2} 7.8 Hz, H-1), 4.52 (dd, 1H, *J*_{6,5} 2.1, *J*_{6,6} 11.7 Hz, H-6a), 4.50 (d, 1H, *J*_{1,2} 8.4 Hz, H-1'), 4.11 (m, 3H, H-6b, H-6a', H-6b'), 3.92 (m, 1H), 3.89 (dd, 1H, *J*_{5,4} ≈ *J*_{5,6} 7.8 Hz, H-5'), 3.80 (dd, 1H, *J*_{4,3} ≈ *J*_{4,5} 9.6 Hz, H-4), 3.69 (m, 1H), 3.61 (m, 4H), 3.52 (m, 2H), 3.44 (m, 1H), 2.16 (s, 3H), 2.13 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.05 (s, 3H), 1.97 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz), δ (ppm): 170.3, 170.3, 170.1, 169.9, 169.8, 169.7, 169.0, 161.4 (NHCHO), 101.0 (C-1'), 100.7 (C-1), 76.1, 72.8, 72.5, 71.8, 70.9, 70.7, 69.8, 69.6, 69.1, 68.6, 66.5, 61.8, 60.8, 37.6, 20.8, 20.8, 20.7, 20.7, 20.7, 20.6, 20.4; ESI-HRMS: *m/z*: calcd for C₃₁H₄₅NNaO₂₀: 774.2427; found: 774.2427.

2-(2-Isocyanoethoxy)ethyl 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glycopyranoside

(4). Following the general procedure for isocyanide synthesis, dehydration of formamide **4** (1.22 g, 1.62 mmol) afforded isocyanide **6** (1.04 g, 1.41 mmol, 87%) as a white solid, *R_f* 0.48 (ethyl acetate/hexanes, 4:1), [α]_D -9.0 (*c* 1.1, CHCl₃); IR (cm⁻¹): 2945, 2883, 2153, 1752, 1223; ¹H NMR (CDCl₃, 600

MHz), δ (ppm): 5.35 (dd, 1H, *J*_{4,5} 1.0, *J*_{4,3} 3.6 Hz, H-4'), 5.21 (dd, 1H, *J*_{3,2} ≈ *J*_{3,4} 9.6 Hz, H-3), 5.11 (dd, 1H, *J*_{2,1} 7.8, *J*_{2,3} 10.2 Hz, H-2'), 4.96 (dd, 1H, *J*_{3,4} 4.6, *J*_{3,2} 10.2 Hz, H-3'), 4.90 (dd, 1H, *J*_{2,1} 7.8, *J*_{2,3} 9.6 Hz, H-2), 4.55 (d, 1H, *J*_{1,2} 7.8 Hz, H-1), 4.51 (dd, 1H, *J*_{6,5} 1.8, *J*_{6,6} 12.0 Hz, H-6a), 4.50 (d, 1H, *J*_{1,2} 7.8 Hz, H-1'), 4.11 (m, 3H, H-6b, H-6a', H-6b'), 3.93 (m, 1H), 3.88 (ddd, 1H, *J*_{5,6a} 1.0, *J*_{5,6b} ≈ *J*_{5,4} 7.2 Hz, H-5'), 3.81 (dd, 1H, *J*_{4,3} ≈ *J*_{4,5} 9.6 Hz, H-4), 3.72 (m, 1H), 3.67 (m, 4H), 3.62 (ddd, 1H, *J*_{5,6a} 2.4, *J*_{5,6b} 5.4, *J*_{5,4} 10.2 Hz, H-5), 3.55 (m, 2H), 2.15 (s, 3H), 2.13 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 1.97 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz), δ (ppm): 170.2, 170.2, 170.0, 169.9, 169.6, 169.5, 168.9, 157.4 (-NC), 100.9 (C-1'), 100.5 (C-1), 76.1, 72.7, 72.6, 71.6, 70.9, 70.6, 70.4, 69.0, 68.9, 68.6, 66.6, 61.9, 60.8, 41.7, 20.8, 20.7, 20.7, 20.6, 20.6, 20.5, 20.5, 20.4; ESI-HRMS: *m/z*: calcd for C₃₁H₄₃NNaO₁₉: 756.2321; found: 756.2315.

2-(2-Azidoethoxy)ethyl 2,3,6-tri-O-acetyl-4-O-[3-O-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)-2,4,6-tri-O-acetyl-β-D-galactopyranosyl]-β-D-glycopyranoside **(3).**

Transesterification of lactose-derived azide **2** was achieved by addition of 1M NaOMe (0.1 mL) to a solution of **2** (701.7 mg, 1.54 mmol) in dry MeOH (10 mL) followed by incubation for 16 h, quenching with DOWEX (H⁺) resin and concentration. Enzymatic α-galactosylation and *O*-acetylation of the residue afforded azide **3** (783.7 mg, 0.755 mmol, 49 %) as a colorless solid, *R_f* 0.45 (ethyl acetate/hexanes, 4:1), [α]_D +41.0 (*c* 0.9, CHCl₃); IR (cm⁻¹, film): 3023, 2960, 1747, 1371, 1223; ¹H NMR (CDCl₃, 600 MHz), δ (ppm): 5.45 (dd, 1H, *J*_{4,5} 1.8, *J*_{4,3} 3.0 Hz, H-4'), 5.33 (d, 1H, *J*_{4,5} 1.2, *J*_{4,3} 3.0 Hz, H-4'), 5.26 (dd, 1H, *J*_{2,1} 3.6, *J*_{2,3} 10.8 Hz, H-2''), 5.25 (d, 1H, *J*_{1,2} 3.6 Hz, H-1''), 5.21 (dd, 1H, *J*_{3,2} ≈ *J*_{3,4} 9.0 Hz, H-3), 5.16 (dd, 1H, *J*_{2,1} 7.8, *J*_{2,3} 10.2 Hz, H-2'), 5.09 (dd, 1H, *J*_{3,4} 3.0, *J*_{3,2} 10.8 Hz, H-3''), 4.90 (dd, 1H, *J*_{2,1} 7.8, *J*_{2,3} 9.6 Hz, H-2), 4.57 (d, 1H, *J*_{1,2} 7.8 Hz, H-1), 4.47 (dd, 1H, *J*_{6,5} 2.4, *J*_{6,6} 12.0 Hz, H-6a), 4.42 (d, 1H, *J*_{1,2} 7.8 Hz, H-1'), 4.20 (dd, 1H, *J*_{5,4} 1.8, *J*_{5,6} 7.2 Hz, H-5''), 4.10 (m, 5H, H-6b, H-6a', H-6b', H-6a'', H-6b''), 3.92 (m, 1H), 3.83 (dd, 1H, *J*_{3,4} 3.0, *J*_{3,2} 10.2 Hz, H-3'), 3.79 (m, 2H, H-4, 1H), 3.73 (m, 3H), 3.67 (m, 2H), 3.60 (m, 3H), 2.15 (s, 3H), 2.14 (s, 3H), 2.14 (s, 3H), 2.11 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 1.95 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz), δ (ppm): 170.4, 170.3, 170.2, 170.1, 169.9, 169.7, 169.7, 169.6, 169.6, 168.7, 101.1 (C-1'), 100.5 (C-1), 93.5 (C-1''), 76.1, 72.9, 72.9, 72.7, 71.7, 71.4, 70.8, 70.3, 69.7, 69.1, 67.7, 67.2, 66.9, 66.5, 64.6, 62.0, 61.3, 61.0, 42.8, 20.8, 20.7, 20.7, 20.7, 20.6, 20.6, 20.6, 20.5, 20.5, 20.5; ESI-HRMS: *m/z*: calcd for C₄₂H₅₉N₃NaO₂₇: 1060.32282; found: 1060.32292.

2-(2-Formamidoethoxy)ethyl 2,3,6-tri-O-acetyl-4-O-[3-O-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)-2,4,6-tri-O-acetyl-β-D-galactopyranosyl]-β-D-glycopyranoside **(5).**

Following the general procedure for formamide synthesis, reduction and subsequent *N*-formylation of azide **3** (717.0 mg, 0.69 mmol) afforded compound **5** (420.7 mg, 0.40 mmol, 59%) as a colorless solid, *R_f* 0.40 (DCM/MeOH, 19:1), [α]_D +33.4 (*c* 0.13, CHCl₃); IR (cm⁻¹): 3392, 2943, 2878, 1747, 1229; ¹H NMR (CDCl₃, 600 MHz), δ (ppm): 8.22 (s, 1H, NHCHO), 6.26 (br s, 1H, NHCHO), 5.45 (dd, 1H, *J*_{4,5} 1.2, *J*_{4,3} 3.0 Hz, H-4''), 5.33 (d, 1H, *J*_{4,3} 2.4 Hz, H-4'), 5.26 (dd, 1H, *J*_{2,1} 3.6, *J*_{2,3} 10.8 Hz, H-2''), 5.25 (d, 1H, *J*_{1,2} 3.6 Hz, H-1''), 5.21 (dd, 1H, *J*_{3,2} ≈ *J*_{3,4} 9.0 Hz, H-3), 5.16 (dd, 1H, *J*_{2,1} 7.8, *J*_{2,3} 10.2 Hz, H-2'), 5.10 (dd, 1H, *J*_{3,4} 3.0, *J*_{3,2} 10.8 Hz, H-3''), 4.89 (dd, 1H, *J*_{2,1} 7.8, *J*_{2,3} 9.0 Hz, H-2), 4.55 (d, 1H, *J*_{1,2} 7.8 Hz, H-1), 4.48 (dd, 1H, *J*_{6,5} 2.4, *J*_{6,6} 12.0 Hz, H-6), 4.43 (d, 1H, *J*_{1,2} 7.8 Hz, H-1'), 4.20 (dd, 1H, *J*_{5,4} ≈ *J*_{5,6} 7.2 Hz, H-5''), 4.10 (m, 5H), 3.93 (m, 1H), 3.83 (dd, 1H, *J*_{3,4} 3.0, *J*_{3,2} 10.2 Hz, H-3'), 3.80 (m, 2H, H-4, 1H),

3.68 (m, 1H), 3.60 (m, 2H), 3.58 (m, 2H), 3.52 (m, 2H), 3.44 (m, 1H), 2.15 (s, 3H), 2.14 (s, 3H), 2.13 (s, 3H), 2.11 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 1.95 (s, 3H); ^{13}C NMR (CDCl_3 , 150 MHz), δ (ppm): 170.4, 170.3, 170.3, 170.3, 170.2, 170.1, 169.9, 169.8, 169.7, 169.6, 168.7, 101.1 (C-1'), 100.7 (C-1), 93.5 (C-1''), 75.9, 72.9, 72.8, 72.6, 71.8, 70.8, 69.8, 69.7, 69.5, 68.9, 67.6, 67.2, 66.8, 66.5, 64.6, 61.9, 61.2, 60.9, 37.6, 20.8, 20.8, 20.8, 20.8, 20.7, 20.7, 20.6, 20.6, 20.5, 20.5; ESI-HRMS: m/z : calcd for $\text{C}_{43}\text{H}_{61}\text{NNaO}_{28}$: 1062.3272; found: 1062.3263.

2-(2-Isocyanatoethoxy)ethyl 2,3,6-tri-O-acetyl-4-O-[3-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)-2,4,6-tri-O-acetyl- β -D-galactopyranosyl]- β -D-glycopyranoside (7).

Dehydration of formamide **5** (420.7 mg, 0.40 mmol) afforded isocyanide **7** (328.3 mg, 0.32 mmol, 80%) as a white solid, R_f 0.44 (ethyl acetate/hexanes, 9:1), $[\alpha]_D +39.7$ (c 1.3, CHCl_3); IR (cm^{-1}): 2961, 2152, 1743, 1220; ^1H NMR (CDCl_3 , 600 MHz), δ (ppm): 5.45 (dd, 1H, $J_{4,5}$ 1.2, $J_{4,3}$ 3.0 Hz, H-4''), 5.33 (d, 1H, $J_{4,3}$ 3.0 Hz, H-4'), 5.26 (dd, 1H, $J_{2,1}$ 3.6, $J_{2,3}$ 10.8 Hz, H-2''), 5.24 (d, 1H, $J_{1,2}$ 3.6 Hz, H-1''), 5.21 (dd, 1H, $J_{3,2} \approx J_{3,4}$ 9.0 Hz, H-3), 5.16 (dd, 1H, $J_{2,1}$ 7.8, $J_{2,3}$ 10.2 Hz, H-2'), 5.10 (dd, 1H, $J_{3,4}$ 3.6, $J_{3,2}$ 10.8 Hz, H-3''), 4.89 (dd, 1H, $J_{2,1}$ 7.8, $J_{2,3}$ 9.0 Hz, H-2), 4.55 (d, 1H, $J_{1,2}$ 7.8 Hz, H-1), 4.48 (dd, 1H, $J_{6,5}$ 2.4, $J_{6,6}$ 12.0 Hz, H-6), 4.43 (d, 1H, $J_{1,2}$ 8.4 Hz, H-1'), 4.21 (dd, 1H, $J_{5,4} \approx J_{5,6}$ 6.4 Hz, H-5''), 4.16 (m, 2H), 4.10 (m, 2H), 4.05 (m, 1H), 3.93 (m, 1H), 3.83 (dd, 1H, $J_{3,4}$ 3.6, $J_{3,2}$ 10.8 Hz, H-3'), 3.80 (m, 2H, H-4, 1H), 3.73 (m, 1H), 3.37 (m, 4H), 3.63 (ddd, 1H, $J_{5,6a}$ 2.4, $J_{5,6b}$ 5.4, $J_{5,4}$ 10.2 Hz, H-5), 3.55 (m, 2H), 2.15 (s, 3H), 2.14 (s, 3H), 2.13 (s, 3H), 2.11 (s, 3H), 2.06 (s, 3H), 2.06 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 1.95 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz), δ (ppm): 170.3, 170.2, 170.2, 170.1, 170.0, 169.8, 169.7, 169.6, 169.6, 168.7, 157.4 (-NC), 100.9 (C-1'), 100.5 (C-1), 93.4 (C-1''), 75.9, 72.8, 72.7, 72.7, 71.7, 70.7, 70.4, 69.7, 68.9, 68.7, 67.6, 66.8, 66.4, 64.6, 61.9, 61.2, 60.9, 60.3, 41.8, 20.8, 20.8, 20.7, 20.7, 20.6, 20.6, 20.6, 20.5, 20.5, 20.4; ESI-HRMS: m/z : calcd for $\text{C}_{43}\text{H}_{59}\text{NNaO}_{27}$: 1044.3167; found: 1044.3155.

U_{NIC1}. Ugi coupling and subsequent deacetylation of trisaccharide isocyanide **7** (81.5 mg, 0.08 mmol) afforded **U_{NIC1}** (45.9 mg, 0.05 mmol, 63%) as a white solid, R_f 0.36 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D +55.2$ (c 0.5, MeOH); IR (cm^{-1} , solid): 3376, 2929, 2883, 1653; ^1H NMR (D_2O , 600 MHz), δ (ppm): 7.25 (m, 1H), 6.97 (m, 1H), 6.89 (m, 1H), 6.82 (m, 1H), 6.79 (m, 1H), 6.72 (m, 2H), 5.13 (s, 1H, H-1''), 4.49 (d, 1H, $J_{1,2}$ 7.2 Hz, H-1'), 4.43 (d, 1H, $J_{1,2}$ 7.2 Hz, H-1), 4.30 (m, 2H), 4.25 (m, 4H), 4.17 (m, 2H), 4.00 (m, 1H), 3.95 (m, 3H), 3.84 (m, 1H), 3.75 (m, 8H), 3.65 (m, 3H), 3.61 (m, 2H), 3.57 (m, 5H), 3.37 (m, 2H), 3.30 (m, 1H); ^{13}C NMR (D_2O , 150 MHz), δ (ppm): 175.1, 171.1, 164.1-114.4 (aromatic Cs), 103.8 (C-1'), 103.0 (C-1), 96.3 (C-1''), 79.6, 78.1, 75.9, 75.6, 75.3, 73.6, 71.7, 70.5, 70.4, 70.2, 70.0, 69.7, 69.7, 69.1, 65.7, 65.4, 65.3, 61.9, 61.8, 61.0, 53.8, 41.2, 39.9; ESI-HRMS: m/z : calcd for $\text{C}_{40}\text{H}_{55}\text{FN}_2\text{NaO}_{21}$: 941.3174; found: 941.3166.

The general procedure for Ugi coupling lactose-derived isocyanide **6** (126.3 mg, 0.17 mmol) followed by transesterification and enzymic α -galactosylation was exemplified to prepare compound **U_{NIC2}**. Final product **U_{NIC2}** (40.0 mg, 0.045 mmol, 41 %) was obtained as a white solid, R_f 0.36 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D +53.4$ (c 0.9, MeOH); IR (cm^{-1} , solid): 3372, 2940, 2873, 2494, 1650; ^1H NMR (D_2O , 500 MHz), δ (ppm): 6.92 (d, 1H, J 8.5 Hz), 6.89 (s, 1H), 6.8 (d, 1H, J 8.5 Hz), 5.12 (d, 1H, $J_{1,2}$ 3.5 Hz, H-1''), 4.49 (d, 1H, $J_{1,2}$ 8.0 Hz, H-1'), 4.44 (d, 1H, $J_{1,2}$ 8.0 Hz, H-1), 4.30 (s, 2H), 4.28 (s, 4H), 4.17 (m, 2H, H-4', H-5''), 3.96 (m, 4H, H-3'', H-4''), H-

6a, H-6b), 3.84 (dd, 1H, $J_{2,1}$ 3.5, $J_{2,3}$ 10.5 Hz, H-2''), 3.77 (m, 3H, H-3', H-5, H-5'), 3.72 (m, 5H, H-6a', H-6b', H-6a'', H-6b'', 1H), 3.64 (m, 5H, H-2', H-3, CH₂, 1H), 3.57 (m, 3H, H-4, CH₂), 3.38 (m, 2H), 3.31 (dd, 1H, $J_{2,1} \approx J_{2,3}$ 8.0 Hz, H-2), 2.19 (d, 2H, J 7.5 Hz), 2.07 (m, 1H), 1.65 (m, 2H), 1.42 (m, 4H), 0.95 (m, 2H); ^{13}C NMR (D_2O , 125 MHz), δ (ppm): 177.7, 171.4, 144.4, 144.2, 136.5, 122.0, 118.9, 117.6, 103.9 (C-1'), 103.1 (C-1), 96.4 (C-1''), 79.7, 78.2, 76.0, 75.7, 75.4, 73.7, 71.8, 70.6, 70.5, 70.3, 70.1, 69.8, 69.8, 69.2, 65.8, 65.5, 61.9, 61.9, 61.1, 53.7, 40.1, 39.9, 37.6, 32.8, 32.8, 25.3, 25.3; ESI-HRMS: m/z : calcd for $\text{C}_{39}\text{H}_{60}\text{N}_2\text{NaO}_{21}$: 915.3581; found: 915.3574.

U_{NIC3}. Ugi coupling and subsequent deacetylation and enzymic α -galactosylation of lactose-derived isocyanide **6** (173.6 mg, 0.24 mmol) afforded final product **U_{NIC3}** (83.7 mg, 0.092 mmol, 75%) as a white solid, R_f 0.36 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D +51.9$ (c 0.5, MeOH); IR (cm^{-1} , solid): 3338, 2921, 2877, 1646; ^1H NMR (D_2O , 500 MHz), δ (ppm): 7.11 (d, 2H, J 8.0 Hz), 6.91 (m, 3H), 6.81 (m, 2H), 5.21 (d, 1H, $J_{1,2}$ 4.0 Hz, H-1''), 4.57 (d, 1H, $J_{1,2}$ 8.0 Hz, H-1'), 4.50 (d, 1H, $J_{1,2}$ 8.0 Hz, H-1), 4.34 (s, 2H), 4.25 (m, 6H, H-4', H-5'', 2 x OCH₂), 4.08 (d, 1H, $J_{4,3}$ 3.0 Hz, H-4''), 4.01 (m, 3H, H-3'', H-6a, H-6b), 3.93 (dd, 1H, $J_{2,1}$ 3.5, $J_{2,3}$ 10.0 Hz, H-2''), 3.87 (m, 3H, H-3', H-5, H-5'), 3.79 (m, 5H, H-6a', H-6b', H-6a'', H-6b'', 1H), 3.72 (m, 5H, H-2', H-3, CH₂, 1H), 3.62 (m, 3H, H-4, CH₂), 3.54 (m, 2H), 3.44 (m, 2H), 3.39 (dd, 1H, $J_{2,1} \approx J_{2,3}$ 9.0 Hz, H-2), 2.28 (s, 3H); ^{13}C NMR (D_2O , 125 MHz), δ (ppm): 175.6, 171.2, 144.4, 144.3, 137.7, 136.1, 132.6, 130.1, 130.1, 129.9, 129.9, 122.0, 118.8, 117.7, 103.9 (C-1'), 103.1 (C-1), 96.4 (C-1''), 76.7, 78.2, 76.0, 75.7, 75.4, 73.7, 71.8, 70.6, 70.5, 70.3, 70.1, 69.8, 69.8, 69.2, 65.8, 65.5, 65.4, 61.9, 61.9, 61.1, 53.8, 41.0, 39.9, 21.1; ESI-HRMS: m/z : calcd for $\text{C}_{41}\text{H}_{58}\text{N}_2\text{NaO}_{21}$: 937.3424; found: 937.3418.

U_{NIC4}. Ugi coupling and subsequent deacetylation and enzymic α -galactosylation of lactose-derived isocyanide **6** (136.9 mg, 0.19 mmol) afforded final product **U_{NIC4}** (73.2 mg, 0.083 mmol, 75 %) as a white solid, R_f 0.36 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D +55.1$ (c 0.3, MeOH); IR (cm^{-1} , solid): 3399, 2932, 2878, 1663, 1068; ^1H NMR (D_2O , 600 MHz), δ (ppm): 6.90 (d, 1H, 3J 9.0 Hz), 6.84 (d, 1H, 4J 1.8 Hz), 6.80 (d, 1H, 3J 9.0, 4J 1.8 Hz), 5.68 (s, 1H), 5.14 (d, 1H, $J_{1,2}$ 3.6 Hz, H-1''), 4.50 (d, 1H, $J_{1,2}$ 7.8 Hz, H-1'), 4.46 (d, 1H, $J_{1,2}$ 7.8 Hz, H-1), 4.42 (s, 2H), 4.29 (s, 4H), 4.19 (m, 2H, H-4', H-5''), 4.01 (d, 1H, $J_{4,3}$ 3.0 Hz, H-4''), 3.95 (m, 3H, H-6a, H-6b, H-3''), 3.85 (dd, 1H, $J_{2,1}$ 4.8, $J_{2,3}$ 10.2, H-2''), 3.78 (m, 3H, H-3', H-5, H-5'), 3.75 (m, 4H, H-6a', H-6b', H-6a'', H-6b'', 1H), 3.67 (m, 3H, H-2', H-3, 1H), 3.64 (m, 2H), 3.58 (m, 3H, H-4, 2H), 3.04 (m, 2H), 3.32 (m, 1H, H-2), 1.90 (s, 2H), 1.59 (s, 3H), 0.72 (s, 3H); ^{13}C NMR (D_2O , 125 MHz), δ (ppm): 171.4, 171.4, 144.0, 143.5, 140.0, 130.1, 121.5, 118.5, 117.0, 103.9 (C-1''), 103.1 (C-1), 96.4 (C-1''), 79.6, 78.2, 76.0, 75.7, 75.4, 73.7, 71.8, 70.6, 70.5, 70.3, 70.1, 69.8, 69.8, 69.8, 69.2, 65.8, 65.5, 65.5, 61.9, 61.9, 61.1, 39.9, 21.5, 14.0, 13.0; ESI-HRMS: m/z : calcd for $\text{C}_{38}\text{H}_{58}\text{N}_2\text{NaO}_{21}$: 901.3424; found: 901.3421.

U_{NIC5}. Ugi coupling and subsequent deacetylation and enzymic α -galactosylation of lactose-derived isocyanide **6** (156.2 mg, 0.21 mmol) afforded final product **U_{NIC5}** (69.0 mg, 0.074 mmol, 63 %) as a white solid, R_f 0.34 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D +50.5$ (c 0.5, MeOH); IR (cm^{-1} , solid): 3375, 2929, 2879, 1645; ^1H NMR (D_2O , 500 MHz), δ (ppm): 8.23 (s, 1H), 8.14 (d, 1H, J 8.0 Hz), 7.80 (d, 1H, J 8.0 Hz), 7.51 (dd, 1H, J 8.0, J 8.0 Hz) 6.86 (s, 1H), 6.79 (d, 1H, J 9.0 Hz), 6.71 (d, 1H, J 8.5 Hz), 5.21 (d, 1H, $J_{1,2}$ 4.0

H₂, H-1''), 4.66 (s, 2H, NHCH₂), 4.58 (d, 1H, *J*_{1,2} 7.5 Hz, H-1'), 4.54 (d, 1H, *J*_{1,2} 8.0 Hz, H-1), 4.25 (m, 2H, H-4', H-5''), 4.17 (m, 4H), 4.09 (d, 1H, *J*_{4,3} 3.0 Hz, H-4''), 4.04 (m, 3H, H-3'', H-6a, H-6b), 3.93 (dd, 1H, *J*_{2,1} 4.0, *J*_{2,3} 10.5 Hz, H-2''), 3.86 (m, 3H, H-3', H-5, H-5'), 3.81 (m, 4H, H-6a', H-6b', H-6a'', H-6b''), 3.78 (m, 6H, H-2', H-3, 2 x CH₂), 3.70 (m, 2H, H-4, 1H), 3.63 (m, 1H), 3.52 (m, 2H, CH₂), 3.40 (dd, 1H, *J*_{2,1} ≈ *J*_{2,3} 8.5 Hz, H-2); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 171.4, 171.9, 148.2, 144.2, 143.8, 136.9, 136.5, 135.5, 130.5, 125.9, 124.2, 122.1, 118.6, 117.5, 103.9 (C-1'), 103.2 (C-1), 96.4 (C-1''), 79.7, 78.2, 76.0, 75.7, 75.4, 73.8, 71.8, 70.6, 70.5, 70.3, 70.1, 69.9, 69.8, 69.2, 65.8, 65.3, 61.9, 61.9, 61.9, 61.2, 54.3, 40.0; ESI-HRMS: *m/z*: calcd for C₃₉H₅₃N₃NaO₂₃: 954.2962; found: 954.2960.

UN₂C₁. Ugi coupling and subsequent deacetylation and enzymatic α-galactosylation of lactose-derived isocyanide **6** (164.1 mg, 0.22 mmol) afforded final product UN₂C₁ (86.0 mg, 0.094 mmol, 59 %) as a white solid, *R_f* 0.36 (DCM/MeOH/H₂O, 7:3:0.5), [α]_D +34.3 (c 1.2, MeOH); IR (cm⁻¹, solid): 3371, 2930, 2497, 1636; ¹H NMR (D₂O, 500 MHz), δ (ppm): 7.33 (m, 0.3H), 7.27 (m, 0.7H), 7.07 (m, 5H), 6.99 (m, 0.3H), 6.95 (m, 0.7H), 6.89 (d, 0.3H, *J* 8.0 Hz), 6.81 (d, 0.7H, *J* 8.0 Hz), 5.67 (dd, 0.3H, *J* 6.5, *J* 8.5 Hz), 5.16 (dd, 0.7H, *J* 6.5, *J* 8.5 Hz), 5.12 (d, 1H, *J*_{1,2} 4.0 Hz, H-1''), 4.48 (d, 1H, *J*_{1,2} 7.5 Hz, H-1'), 4.43 (d, 0.7H, *J*_{1,2} 8.0 Hz, H-1), 4.37 (d, 0.3H, *J*_{1,2} 8.0 Hz, H-1), 4.17 (m, 2H, H-4', H-5''), 3.99 (d, 1H, *J*_{4,3} 3.0 Hz, H-4''), 3.92 (m, 5H, H-3'', H-6a, H-6b, CH₂), 3.84 (dd, 1H, *J*_{2,1} 4.0, *J*_{2,3} 10.5 Hz, H-2''), 3.76 (m, 3H, H-3', H-5, H-5'), 3.73 (s, 2H), 3.69 (m, 4H, H-6a', H-6b', H-6a'', H-6b''), 3.67 (m, 3H, H-2', H-3, 1H), 3.56 (m, 6H, H-4, 2 x CH₂, 1H), 3.33 (m, 2H), 3.25 (m, H-2), 2.66 (m, 2H), 1.98 (m, 1H), 1.84 (m, 1H), 1.61 (m, 2H); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 176.0, 175.2, 171.5, 171.5, 164.6-114.8 (aromatic Cs), 103.9 (C-1'), 103.1 (C-1), 96.4 (C-1''), 79.7, 78.2, 76.0, 75.7, 75.4, 73.7, 71.8, 70.5, 70.5, 70.4, 70.3, 70.1, 69.8, 69.7, 69.2, 65.8, 61.9, 61.9, 61.1, 59.1, 55.4, 47.9, 41.0, 40.8, 39.9, 39.8, 29.7, 29.5, 29.4, 28.3, 22.2, 22.1; ESI-HRMS: *m/z*: calcd for C₄₂H₅₉FN₂NaO₁₉: 937.3588; found: 937.3585.

UN₂C₂. Ugi coupling and subsequent Zemplén deacetylation and enzymatic α-galactosylation of lactose-derived isocyanide **6** (181.1 mg, 0.25 mmol) afforded final product UN₂C₂ (67.0 mg, 0.075 mmol, 45 %) as a white solid, *R_f* 0.40 (DCM/MeOH/H₂O, 7:3:0.5), [α]_D +42.5 (c 0.6, MeOH); IR (cm⁻¹, solid): 3362, 2934, 2866, 1628; ¹H NMR (D₂O, 500 MHz), δ (ppm): 7.32 (m, 3H), 7.16 (d, 0.6H, *J* 7.3 Hz), 7.07 (d, 0.4H, *J* 7.3 Hz), 5.80 (dd, 0.4H, *J* 5.9, *J* 9.2 Hz), 5.39 (dd, 0.4H, *J* 5.9, *J* 9.2 Hz), 5.21 (d, 1H, *J*_{1,2} 3.9 Hz, H-1''), 4.57 (d, 1H, *J*_{1,2} 7.8 Hz, H-1''), 4.55 (d, 0.6H, *J*_{1,2} 8.0 Hz, H-1'), 4.53 (d, 0.4H, *J*_{1,2} 8.0 Hz, H-1), 4.26 (m, 2H, H-4', H-5''), 4.08 (d, 1H, *J*_{4,3} 3.0 Hz, H-4''), 4.00 (m, 3H, H-3'', H-6a, H-6b), 3.93 (dd, 1H, *J*_{2,1} 3.9, *J*_{2,3} 10.3 Hz, H-2''), 3.85 (m, 3H, H-3', H-5, H-5'), 3.76 (m, 4H, H-6a', H-6b', H-6a'', H-6b''), 3.71 (m, 6H, H-2', H-3, 2 x CH₂), 3.65 (m, 3H, H-4, CH₂), 3.44 (m, 2H), 3.38 (m, H-2), 2.84 (m, 2H), 2.73 (m, 0.6H), 2.52 (m, 0.4H), 2.34 (m, 2H), 2.09 (m, 1H), 1.89 (m, 4H), 1.71 (m, 3H), 1.62 (m, 2H), 1.30 (m, 2H); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 178.9, 178.4, 172.0, 172.0, 140.5, 140.3, 135.2, 135.0, 130.6, 130.5, 128.7, 128.5, 128.1, 127.7, 127.3, 127.2, 103.8 (C-1'), 103.1 (C-1), 96.4 (C-1''), 79.6, 78.2, 76.0, 75.7, 75.4, 75.4, 73.7, 71.8, 70.5, 70.5, 70.4, 70.3, 70.1, 69.8, 69.8, 69.7, 69.2, 65.8, 61.9, 61.9, 61.1, 58.9, 47.8, 40.4, 40.0, 39.8, 39.7, 37.7, 37.5, 33.2, 33.2, 33.0, 33.0, 29.7, 29.6, 29.5, 28.3, 25.5, 25.5, 25.4, 25.4, 22.3, 22.2; ESI-HRMS: *m/z*: calcd for C₄₁H₆₄N₂NaO₁₉: 911.3995; found: 911.3990.

UN₂C₃. Ugi coupling and subsequent deacetylation and enzymatic α-galactosylation of lactose-derived isocyanide **6** (185.1 mg, 0.25 mmol) afforded final product UN₂C₃ (114.0 mg, 0.13 mmol, 52%) as a white solid, *R_f* 0.40 (DCM/MeOH/H₂O, 7:3:0.5), [α]_D +33.7 (c 0.8, MeOH); IR (cm⁻¹, solid): 3339, 2928, 2502, 1653; ¹H NMR (D₂O, 600 MHz), δ (ppm): 7.13-6.70 (m, 8H), 5.65 (m, 0.4H), 5.13 (d, 1H, *J*_{1,2} 4.2 Hz, H-1''), 5.06 (m, 0.6H), 4.48 (d, 1H, *J*_{1,2} 7.8 Hz, H-1'), 4.41 (d, 0.6H, *J*_{1,2} 7.8 Hz, H-1), 4.35 (d, 0.4H, *J*_{1,2} 7.8 Hz, H-1), 4.18 (m, 2H, H-5'', H-4'), 3.99 (d, 1H, *J*_{4,3} 3.0 Hz, H-4''), 3.94 (m, 3H, H-3'', H-6a, H-6b), 3.86 (dd, 1H, *J*_{2,1} 3.6, *J*_{2,3} 10.2 Hz, H-2''), 3.80 (m, 5H, H-3', H-5, H-5', CH₂), 3.71 (m, 5H, H-6a', H-6b', H-6a'', H-6b''), 3.68 (m, 6H, H-2', H-3, 2 x CH₂), 3.55 (m, 4H, H-4, CH₂, 1H), 3.31 (m, 2H), 3.26 (m, H-2), 2.26 (m, 2H), 2.17 (s, 1.2H), 2.10 (s, 1.8H), 1.87 (m, 2H), 1.54 (m, 2H); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 176.2, 175.5, 171.4, 171.3, 140.3-126.9 (aromatic Cs), 103.9 (C-1'), 103.2 (C-1), 96.4 (C-1''), 79.7, 78.3, 76.0, 75.7, 75.4, 73.7, 71.8, 70.6, 70.5, 70.4, 70.3, 70.1, 69.9, 69.7, 69.2, 65.8, 61.9, 61.9, 61.2, 59.1, 48.7, 47.8, 41.3, 41.0, 39.8, 29.7, 29.6, 29.4, 28.3, 22.4, 21.3, 21.3; ESI-HRMS: *m/z*: calcd for C₄₃H₆₂N₂NaO₁₉: 933.3839; found: 933.3834.

UN₂C₄. Ugi coupling and subsequent deacetylation and enzymatic α-galactosylation of lactose-derived isocyanide **6** (122.0 mg, 0.17 mmol) afforded final product UN₂C₄ (65.2 mg, 0.075 mmol, 64 %) as a white solid, *R_f* 0.42 (DCM/MeOH/H₂O, 7:3:0.5), [α]_D +46.0 (c 0.5, MeOH); IR (cm⁻¹, solid): 3370, 2929, 2874, 2492, 1662; ¹H NMR (D₂O, 500 MHz), δ (ppm): 7.24 (m, 2H), 7.19 (m, 1H), 7.11 (m, 1H), 5.81 (ddd, 0.8H, *J* 1.5, *J* 7.5, *J* 7.5 Hz), 5.71 (ddd, 0.2H, *J* 1.5, *J* 7.5, *J* 7.5 Hz), 5.59 (dd, 0.2H, *J* 6.0, 10.5 Hz), 5.24 (dd, 0.8H, *J* 6.0, 10.5 Hz), 5.13 (d, 1H, *J*_{1,2} 4.0 Hz, H-1''), 4.49 (d, 1H, *J*_{1,2} 8.0 Hz, H-1'), 4.46 (d, 0.8H, *J*_{1,2} 8.0 Hz, H-1), 4.44 (d, 0.2H, *J*_{1,2} 8.0 Hz, H-1), 4.17 (m, 2H, H-4', H-5''), 4.00 (d, 1H, *J*_{4,3} 3.5 Hz, H-4''), 3.95 (m, 5H, H-3'', H-6a, H-6b, CH₂), 3.84 (dd, *J*_{2,1} 3.5, *J*_{2,3} 10.0 Hz, H-2''), 3.77 (m, 3H, H-3', H-5, H-5'), 3.68 (m, 4H, H-6a', H-6b', H-6a'', H-6b''), 3.61 (m, 6H, H-2', H-3, 2 x CH₂), 3.53 (m, 3H, H-4, CH₂), 3.36 (m, 2H), 3.29 (m, H-2), 2.74 (m, 2H), 2.11 (m, 3H), 1.94 (m, 1H), 1.89 (s, 3H), 1.75 (m, 2H), 0.95 (dd, 3H, *J* 8.0, *J* 8.0); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 178.9, 178.8, 171.8, 171.5, 140.4, 140.3, 135.9, 135.1, 135.1, 135.0, 130.6, 130.5, 130.3, 128.7, 128.5, 127.9, 127.8, 127.4, 127.3, 103.9 (C-1'), 103.1 (C-1), 96.4 (C-1''), 79.7, 78.2, 76.0, 75.7, 75.4, 73.7, 71.8, 70.6, 70.5, 70.3, 70.1, 69.8, 69.2, 65.8, 61.9, 61.9, 61.1, 60.3, 55.5, 50.4, 46.9, 39.8, 29.7, 29.6, 29.5, 28.2, 22.3, 22.2, 21.5, 21.5, 14.5, 13.5; ESI-HRMS: *m/z*: calcd for C₄₀H₆₂N₂NaO₁₉: 897.3839; found: 897.3836.

UN₂C₅. Ugi coupling and subsequent deacetylation and enzymatic α-galactosylation of lactose-derived isocyanide **6** (152.1 mg, 0.21 mmol) afforded final product UN₂C₅ (73.5 mg, 0.079 mmol, 52 %) as a white solid, *R_f* 0.38 (DCM/MeOH/H₂O, 7:3:0.5), [α]_D +14.4 (c 0.5, MeOH); IR (cm⁻¹, solid): 3378, 2933, 2883, 2504, 1628; ¹H NMR (D₂O, 500 MHz), δ (ppm): 8.30-6.85 (m, 8H), 5.67 (m, 0.2H), 5.13 (d, 1H, *J*_{1,2} 4.0 Hz, H-1''), 4.77 (m, 0.8H), 4.48 (d, 1H, *J*_{1,2} 7.5 Hz, H-1'), 4.44 (d, 0.8H, *J*_{1,2} 8.0 Hz, H-1'), 4.37 (d, 0.2H, *J*_{1,2} 8.0 Hz, H-1'), 4.17 (m, 2H, H-5'', H-4'), 4.00 (d, 1H, *J*_{4,3} 3.0 Hz, H-4''), 3.94 (m, 5H, H-3'', H-6a, H-6b, CH₂), 3.84 (dd, 1H, *J*_{2,1} 4.0, *J*_{2,3} 10.5 Hz, H-2''), 3.77 (m, 3H, H-3', H-5, H-5'), 3.69 (m, 4H, H-6a', H-6b', H-6a'', H-6b''), 3.62 (m, 6H, H-2', H-3, 2 x CH₂), 3.59 (m, 3H, H-4, CH₂), 3.52 (m, 1H), 3.39 (m, 1H), 3.28 (dd, 0.8H, *J*_{2,1} 8.0, *J*_{2,3} 9.5 Hz, H-2), 3.26 (dd, 0.2H, *J*_{2,1} 8.0, *J*_{2,3} 9.5 Hz, H-2), 2.54 (m, 2H), 2.07 (m, 1H), 1.73 (m, 2H), 1.27 (m, 2H); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 173.6,

172.9, 170.8, 173.7, 148.8-122.1 (aromatic Cs), 103.8 (C-1'), 103.0 (C-1), 96.3 (C-1''), 79.6, 78.1, 75.9, 75.6, 75.5, 75.2, 73.6, 71.7, 70.4, 70.3, 70.2, 70.1, 69.8, 69.6, 69.5, 69.4, 69.1, 65.7, 61.8, 61.8, 61.0, 60.5, 47.3, 39.8, 39.6, 29.6, 29.3, 22.0; ESI-HRMS: m/z : calcd for $C_{41}H_{57}N_3NaO_{21}$: 950.3377; found: 950.3371.

U_{N3C1}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (162.6 mg, 0.22 mmol) afforded final product **U_{N3C1}** (84.9 mg, 0.094 mmol, 76 %) as a white solid, R_f 0.40 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D^{+55.4}$ (*c* 0.5, MeOH); IR (cm⁻¹, solid): 3389, 2892, 1655, 1075; ¹H NMR (D₂O, 600 MHz), δ (ppm): 7.27 (m, 1H), 6.98 (m, 1H), 6.87 (s, 1H), 6.85 (s, 1H), 6.79 (m, 2H), 6.76 (d, 1H, J 1.8 Hz), 5.99 (s, 2H), 5.13 (d, 1H, $J_{1,2}$ 4.2 Hz, H-1''), 4.49 (d, 1H, $J_{1,2}$ 7.8 Hz, H-1'), 4.44 (d, 1H, $J_{1,2}$ 7.8 Hz, H-1), 4.32 (s, 2H), 4.19 (dd, 1H, $J_{5,6a} \approx J_{5,6b}$ 6.0 Hz, H-5''), 4.17 (d, 1H, $J_{4,3}$ 3.0 Hz, H-4'), 4.01 (d, 1H, $J_{4,3}$ 3.6 Hz, H-4''), 3.96 (m, 3H, H-3'', H-6a, H-6b), 3.85 (d, 1H, $J_{2,1}$ 4.2, $J_{2,3}$ 10.2, H-2''), 3.77 (m, 3H, H-3', H-5, H-5'), 3.72 (m, 5H, H-6a', H-6b', H-6a'', H-6b'', 1H), 3.66 (m, 3H, H-2', H-3, 1H), 3.59 (m, 6H, H-4, 2 x CH₂, 1H), 3.54 (m, 1H), 3.39 (m, 2H), 3.30 (m, 1H, H-2); ¹³C NMR (D₂O, 150 MHz), δ (ppm): 175.2, 171.2, 163.4-109 (aromatic Cs), 103.8 (C-1'), 103.0, 102.9 (C-1), 96.3 (C-1''), 79.6, 78.1, 75.9, 75.6, 75.3, 73.6, 71.7, 70.5, 70.4, 70.2, 70.0, 69.7, 69.7, 69.1, 61.9, 61.8, 61.0, 53.8, 41.1, 39.9; ESI-HRMS: m/z : calcd for $C_{39}H_{53}FN_2NaO_{21}$: 927.3017; found: 927.3011.

U_{N3C2}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (122.6 mg, 0.17 mmol) afforded final product **U_{N3C2}** (54.4 mg, 0.062 mmol, 81 %) as a white solid, R_f 0.36 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D^{+56.9}$ (*c* 0.6, MeOH); IR (cm⁻¹, solid): 3388, 2944, 1658, 1074; ¹H NMR (D₂O, 600 MHz), δ (ppm): 6.90 (d, 1H, J 8.4 Hz), 6.89 (d, 1H, J 1.8 Hz), 6.85 (dd, 1H, J 1.8, J 8.4 Hz), 6.02 (s, 2H), 5.14 (d, 1H, $J_{1,2}$ 4.2 Hz, H-1''), 4.50 (d, 1H, $J_{1,2}$ 8.4 Hz, H-1'), 4.46 (d, 1H, $J_{1,2}$ 7.8 Hz, H-1), 4.32 (s, 2H), 4.18 (m, 2H, H-5'', H-4'), 4.00 (m, 2H, H-4', H-6a), 3.95 (m, 2H, H-6b, H-3''), 3.85 (dd, 1H, $J_{2,1}$ 3.9, $J_{2,3}$ 10.2, H-2''), 3.78 (m, 3H, H-5, H-5'), 3.73 (m, 4H, H-6a', H-6b', H-6a'', H-6b''), 3.68 (m, 2H, H-2', H-3), 3.62 (m, 4H), 3.60 (dd, 1H, $J_{4,5} \approx J_{4,3}$ 8.4 Hz, H-4), 3.57 (m, 2H), 3.41 (m, 2H), 3.31 (m, 1H), 2.23 (d, 2H, J 7.2 Hz), 2.09 (m, 1H), 1.67 (m, 2H), 1.44 (m, 4H), 0.99 (m, 2H); ¹³C NMR (D₂O, 150 MHz), δ (ppm): 177.8, 171.4, 148.8, 148.1, 136.7, 122.4, 109.5, 109.4, 103.7 (C-1'), 103.1, 102.9 (C-1), 96.3 (C-1''), 79.6, 78.1, 75.9, 75.6, 75.3, 73.7, 71.7, 70.5, 70.4, 70.2, 70.0, 69.7, 69.7, 69.1, 65.7, 61.9, 61.8, 61.1, 53.7, 40.1, 39.8, 37.5, 32.7, 32.7, 25.2, 25.2; ESI-HRMS: m/z : calcd for $C_{38}H_{58}N_2NaO_{21}$: 901.3424; found: 901.3420.

U_{N3C3}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (182.7 mg, 0.25 mmol) afforded final product **U_{N3C3}** (78.0 mg, 0.087 mmol, 54 %) as a white solid, R_f 0.38 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D^{+55.8}$ (*c* 0.7, MeOH); IR (cm⁻¹, solid): 3369, 2890, 1650; ¹H NMR (D₂O, 500 MHz), δ (ppm): 7.12 (d, J 8.0 Hz, 2H), 6.93 (d, J 8.0 Hz, 2H), 6.86 (d, J 8.0 Hz, 1H), 6.78 (dd, J 2.0, J 8.0 Hz, 1H), 6.74 (d, J 2.0 Hz, 1H), 5.99 (s, 2H), 5.12 (d, $J_{1,2}$ 4.0 Hz, H-1''), 4.48 (d, $J_{1,2}$ 7.5 Hz, H-1'), 4.43 (d, $J_{1,2}$ 7.5 Hz, H-1), 4.13 (s, NCH₂), 4.17 (m, H-4', H-5''), 4.00 (d, $J_{4,3}$ 3.0 Hz, H-4''), 3.94 (m, H-3'', H-6a, H-6b), 3.84 (dd, $J_{2,1}$ 3.5, $J_{2,3}$ 10.0 Hz, H-2''), 3.75 (m, H-3', H-5, H-5'), 3.70 (m, H-6a', H-6b', H-6a'', H-6b''), 3.64 (m, H-2', H-3, 2 x CH₂), 3.58 (m, H-4, 2 x CH₂), 3.39 (m, CH₂), 3.29 (dd, $J_{2,1}$ 8.0, $J_{2,3}$ 9.5 Hz, H-2), 2.27 (s, 3H); ¹³C NMR (D₂O, 125

MHz), δ (ppm): 175.8, 171.3, 148.8, 148.2, 137.9, 136.5, 132.6, 130.1, 130.1, 129.9, 129.9, 122.6, 109.5, 109.5, 103.9 (C-1'), 103.1 (C-1), 102.9, 96.4 (C-1''), 79.7, 78.2, 76.0, 75.7, 75.4, 73.7, 71.8, 70.5, 70.5, 70.3, 70.1, 69.8, 69.8, 69.2, 65.8, 61.9, 61.9, 61.1, 53.9, 40.9, 39.9, 21.1; ESI-HRMS: m/z : calcd for $C_{40}H_{56}N_2NaO_{21}$: 923.3268; found: 923.3260.

U_{N3C4}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (141.1 mg, 0.19 mmol) afforded final product **U_{N3C4}** (81.5 mg, 0.094 mmol, 70 %) as a white solid, R_f 0.34 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D^{+56.9}$ (*c* 0.7, MeOH); IR (cm⁻¹, solid): 3390, 2928, 2891, 1662, 1066; ¹H NMR (D₂O, 600 MHz), δ (ppm): 6.87 (d, 1H, J 8.4 Hz), 6.84 (d, 1H, J 1.8 Hz), 6.78 (dd, 1H, J 1.8, J 8.4 Hz), 5.99 (s, 2H), 5.71 (s, 1H), 5.14 (d, 1H, $J_{1,2}$ 3.6 Hz, H-1''), 4.50 (d, 1H, $J_{1,2}$ 7.8 Hz, H-1'), 4.46 (d, 1H, $J_{1,2}$ 8.4 Hz, H-1), 4.42 (s, 2H), 4.18 (m, 2H, H-5'', H-4'), 4.01 (d, 1H, $J_{4,3}$ 3.6 Hz, H-4''), 3.95 (m, 3H, H-3'', H-6a, H-6b), 3.85 (dd, 1H, $J_{2,1}$ 4.2, $J_{2,3}$ 10.8, H-2''), 3.77 (m, 3H, H-3', H-5, H-5'), 3.72 (m, 5H, H-6a', H-6b', H-6a'', H-6b'', 1H), 3.67 (m, 3H, H-2', H-3, 1H), 3.63 (m, 2H), 3.59 (dd, 1H, $J_{4,5} \approx J_{4,3}$ 8.4 Hz, H-4), 3.56 (m, 2H), 3.41 (m, 2H), 3.32 (dd, 1H, $J_{1,2}$ 7.8, $J_{2,3}$ 5.4 Hz, H-2), 1.92 (s, 2H), 1.59 (s, 3H), 0.74 (s, 3H); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 171.3, 171.3, 148.4, 147.4, 140.0, 130.1, 121.8, 109.2, 109.1, 109.0, 103.8 (C-1'), 103.0, 102.7 (C-1), 96.3 (C-1''), 79.5, 78.1, 75.9, 75.6, 75.3, 73.6, 71.7, 70.4, 70.4, 70.2, 70.0, 70.0, 69.7, 69.7, 69.1, 65.7, 61.8, 61.8, 61.0, 39.8, 21.3, 13.9, 12.9; ESI-HRMS: m/z : calcd for $C_{37}H_{56}N_2NaO_{21}$: 887.3268; found: 887.3263.

U_{N3C5}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (108.5 mg, 0.15 mmol) afforded final product **U_{N3C5}** (24.0 mg, 0.026 mmol, 18%) as a white solid, R_f 0.38 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D^{+54.9}$ (*c* 0.5, MeOH); IR (cm⁻¹, solid): 3382, 2889, 1646; ¹H NMR (D₂O, 600 MHz), δ (ppm): 8.21 (s, 1H), 8.14 (d, 1H, J 8.4 Hz), 7.74 (d, 1H, J 7.8 Hz), 7.48 (dd, 1H, J 7.8, J 7.8 Hz), 6.81 (s, 1H), 6.72 (dd, 1H, J 1.8, J 7.8 Hz), 6.66 (d, 1H, J 8.4 Hz), 5.87 (s, 2H), 5.13 (d, 1H, J 3.6 Hz, H-1''), 4.49 (d, 1H, J 7.8 Hz, H-1'), 4.47 (d, 1H, J 7.8 Hz, H-1), 4.18 (m, 2H, H-4', H-5''), 4.00 (d, 1H, J 3.0 Hz, H-4''), 3.99 (dd, 1H, $J_{3,4}$ 4.2, $J_{3,2}$ 8.4, Hz, H-3''), 3.96 (m, 2H, H-6a, H-6b), 3.85 (dd, 1H, $J_{2,1}$ 3.6, $J_{2,3}$ 10.2, Hz, H-2''), 3.78 (m, 5H, H-3', H-5, H-5', CH₂), 3.73 (m, 4H, H-6a', H-6b', H-6a'', H-6b), 3.67 (m, 6H, H-2', H-3, 2 x CH₂), 3.62 (m, 2H, H-4, 1H), 3.57 (m, 1H), 3.46 (m, 2H), 3.31 (dd, 1H, $J_{2,1} \approx J_{2,3}$ 9.0, Hz, H-2); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 171.7, 171.0, 148.7, 148.3, 147.8, 136.9, 136.8, 135.4, 130.6, 125.9, 124.2, 122.8, 109.4, 109.3, 103.9 (C-1'), 103.1 (C-1), 102.9, 96.4 (C-1''), 79.7, 78.2, 76.0, 75.7, 75.4, 73.7, 71.8, 70.5, 70.5, 70.3, 70.1, 69.8, 69.8, 69.2, 65.8, 61.9, 61.9, 61.1, 54.4, 40.0; ESI-HRMS: m/z : calcd for $C_{38}H_{51}N_3NaO_{23}$: 940.2806; found: 940.2799.

U_{N4C1}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (148.9 mg, 0.20 mmol) afforded final product **U_{N4C1}** (57.4 mg, 0.063 mmol, 58 %) as a white solid, R_f 0.40 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D^{+54.8}$ (*c* 0.8, MeOH); IR (cm⁻¹, solid): 3367, 2929, 2508, 1653; ¹H NMR (D₂O, 500 MHz), δ (ppm): 7.03 (m, 1H), 6.91 (d, 1H, J 7.0 Hz), 6.89 (d, 1H, J 7.0 Hz), 6.69 (m, 3H), 6.35 (d, 1H, J 9.5 Hz), 5.12 (d, 1H, $J_{1,2}$ 3.5 Hz, H-1''), 4.48 (d, 1H, $J_{1,2}$ 7.5 Hz, H-1'), 4.40 (d, 1H, $J_{1,2}$ 8.0 Hz, H-1), 4.17 (m, 4H), 3.99 (d, 1H, $J_{4,3}$ 3.0 Hz, H-4''), 3.93 (m, 3H, H-3'', H-6a, H-6b), 3.84 (dd, 1H, $J_{2,1}$ 3.5, $J_{2,3}$ 10.5 Hz, H-2''), 3.78 (m, 3H, H-3', H-5, H-5'), 3.72 (m, 6H, H-6a', H-6b', H-6a'', H-6b'', CH₂), 3.61 (m, 4H, H-2', H-3, CH₂), 3.50 (m, 3H, H-4, CH₂), 3.31 (m, 5H), 2.39 (m, 4H), 1.42 (m, 4H);

^{13}C NMR (D_2O , 125 MHz), δ (ppm): 173.6, 170.4, 164-114.1 (aromatic Cs), 103.9 (C-1'), 103.2 (C-1), 96.4 (C-1''), 79.7, 78.3, 76.0, 75.7, 75.4, 73.8, 71.8, 70.6, 70.5, 70.3, 70.1, 69.9, 69.7, 69.2, 65.8, 61.9, 61.9, 61.2, 53.7, 41.2, 39.9, 29.7, 29.5, 23.6, 23.5; ESI-HRMS: m/z : calcd for $\text{C}_{42}\text{H}_{59}\text{FN}_2\text{NaO}_{10}$: 937.3588; found: 937.3583.

U_{N4C2}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (158.8 mg, 0.22 mmol) afforded final product **U_{N4C2}** (78.0 mg, 0.088 mmol, 79 %) as a white solid, R_f 0.40 (DCM/MeOH/ H_2O , 7:3:0.5), $[\alpha]_D +58.0$ (c 0.5, MeOH); IR (cm^{-1} , solid): 3352, 2932, 2866, 1653; ^1H NMR (D_2O , 500 MHz), δ (ppm): 7.09 (m, 2H), 7.00 (d, 1H, J 8.0 Hz), 5.21 (d, 1H, $J_{1,2}$ 4.0 Hz, H-1''), 4.58 (d, 1H, $J_{1,2}$ 7.5 Hz, H-1'), 4.52 (d, 1H, $J_{1,2}$ 8.0 Hz, H-1), 4.35 (s, 2H), 4.26 (m, 2H, H-4', H-5''), 4.08 (d, 1H, $J_{4,3}$ 3.0 Hz, H-4''), 4.03 (m, 3H, H-3''), H-6a, H-6b), 3.93 (dd, 1H, $J_{2,1}$ 3.5, $J_{2,3}$ 10.0 Hz, H-2''), 3.86 (m, 3H, H-3', H-5, H-5''), 3.81 (m, 5H, H-6a', H-6b', H-6a'', H-6b'', 1H), 3.72 (m, 5H, H-2', H-3, CH₂, 1H), 3.63 (m, 3H, H-4, CH₂), 3.45 (m, 2H), 3.41 (dd, 1H, $J_{2,1} \approx J_{2,3}$ 8.5 Hz, H-2), 2.66 (m, 4H), 2.17 (m, 3H), 1.64 (m, 6H), 1.38 (m, 4H), 0.88 (m, 2H); ^{13}C NMR (D_2O , 125 MHz), δ (ppm): 175.9, 170.7, 141.2, 139.3, 137.8, 131.1, 129.1, 125.9, 103.9 (C-1'), 103.2 (C-1), 96.4 (C-1''), 79.7, 78.3, 76.0, 75.8, 75.4, 73.8, 71.8, 70.6, 70.6, 70.3, 70.1, 69.9, 69.7, 69.2, 65.8, 61.9, 61.9, 61.2, 53.7, 40.2, 39.9, 37.6, 33.0, 33.0, 29.9, 29.7, 25.5, 25.5, 23.8, 23.7; ESI-HRMS: m/z : calcd for $\text{C}_{41}\text{H}_{64}\text{N}_2\text{NaO}_{19}$: 911.3995; found: 911.3992.

U_{N4C3}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (167.3 mg, 0.23 mmol) afforded final product **U_{N4C3}** (56.5 mg, 0.062 mmol, 56 %) as a white solid, R_f 0.40 (DCM/MeOH/ H_2O , 7:3:0.5), $[\alpha]_D +49.3$ (c 0.5, MeOH); IR (cm^{-1} , solid): 3353, 2926, 1652; ^1H NMR (D_2O , 500 MHz), δ (ppm): 7.02 (d, 1H, J 7.0 Hz), 6.85 (m, 4H), 6.76 (d, 2H, J 7.5 Hz), 5.21 (d, 1H, $J_{1,2}$ 3.5 Hz, H-1''), 4.57 (d, 1H, $J_{1,2}$ 8.0 Hz, H-1'), 4.48 (d, 1H, $J_{1,2}$ 8.0 Hz, H-1), 4.26 (m, 4H, H-4', H-5''), CH₂), 4.08 (d, 1H, $J_{4,3}$ 3.0 Hz, H-4''), 4.02 (m, 3H, H-3''), H-6a, H-6b), 3.93 (dd, 1H, $J_{2,1}$ 3.5, $J_{2,3}$ 10.5 Hz, H-2''), 3.86 (m, 3H, H-3', H-5, H-5''), 3.78 (m, 6H, H-6a', H-6b', H-6a'', H-6b'', 1H), 3.70 (m, 4H, H-2', H-3, CH₂), 3.58 (m, 3H, H-4, CH₂), 3.40 (m, 4H), 3.34 (m, 1H, H-2), 2.42 (m, 4H), 2.08 (s, 3H), 1.45 (m, 4H); ^{13}C NMR (D_2O , 125 MHz), δ (ppm): 174.2, 170.4, 140.8, 139.0, 137.8, 136.8, 132.9, 130.9, 129.8, 129.8, 129.8, 129.3, 125.9, 125.9, 103.9 (C-1'), 103.2 (C-1), 96.4 (C-1''), 79.8, 78.4, 78.3, 76.0, 75.7, 75.4, 73.8, 71.8, 70.6, 70.3, 70.1, 69.9, 69.7, 69.2, 65.8, 61.9, 61.9, 61.2, 53.8, 40.9, 39.9, 29.7, 29.7, 23.7, 23.5, 21.4; ESI-HRMS: m/z : calcd for $\text{C}_{43}\text{H}_{62}\text{N}_2\text{NaO}_{19}$: 933.3839; found: 933.3832.

U_{N4C4}. Ugi coupling and subsequent Zemplén deacetylation of trisaccharide isocyanide **7** (70.1 mg, 0.069 mmol) afforded **U_{N4C4}** (40.2 mg, 0.046 mmol, 67%) as a white solid, R_f 0.38 (DCM/MeOH/ H_2O , 7:3:0.5), $[\alpha]_D +54.6$ (c 0.2, MeOH); IR (cm^{-1} , solid): 3390, 2928, 2891, 1662, 1066; ^1H NMR (D_2O , 600 MHz), δ (ppm): 7.13 (d, J 9.0 Hz, 1H), 7.00 (m, 2H), 5.70 (s, 1H), 5.14 (d, $J_{1,2}$ 1.8 Hz, H-1''), 4.51 (d, $J_{1,2}$ 7.8 Hz, H-1'), 4.45 (m, H-1, NCH₂), 4.19 (m, H-5'', H-4'), 4.02 (m, H-4''), 3.96 (m, H-3'', H-6a, H-6b), 3.86 (dd, $J_{2,1}$ 1.8, $J_{2,3}$ 10.2 Hz, H-2''), 3.79 (m, H-3', H-5, H-5''), 3.74 (m, H-6a', H-6b', H-6a'', H-6b'', 1H), 3.65 (m, H-2', H-3, -CH₂, 1H), 3.58 (m, H-4, CH₂), 3.40 (m, CH₂), 3.32 (dd, $J_{2,1} \approx J_{2,3}$ 7.8 Hz, H-2), 2.73 (m, 4H), 1.90 (m, 2H), 1.75 (m, 4H), 1.59 (s, 3H), 0.71 (s, 3H); ^{13}C NMR (D_2O , 125 MHz), δ (ppm): 171.4, 171.4, 141.6, 139.5, 138.0, 130.7, 130.3, 128.4, 124.8, 103.9 (C-1'), 103.1 (C-1), 96.4 (C-1''), 79.6, 78.2, 76.0, 75.7, 75.4, 73.7, 71.8, 70.6, 70.5,

70.3, 70.1, 69.8, 69.8, 69.8, 69.2, 65.8, 61.9, 61.9, 61.1, 53.8, 39.9, 29.8, 29.5, 23.6, 23.5, 21.5, 14.1, 12.9; ESI-HRMS: m/z : calcd for $\text{C}_{40}\text{H}_{62}\text{N}_2\text{NaO}_{19}$: 897.3839; found: 897.3828.

U_{N4C5}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (143.2 mg, 0.20 mmol) afforded final product **U_{N4C5}** (85.0 mg, 0.092 mmol, 69 %) as a white solid, R_f 0.38 (DCM/MeOH/ H_2O , 7:3:0.5), $[\alpha]_D +56.2$ (c 0.8, MeOH); IR (cm^{-1} , solid): 3363, 2930, 1646; ^1H NMR (D_2O , 500 MHz), δ (ppm): 8.04 (s, 1H), 7.77 (m, 2H), 7.2 (s, 1H), 6.90 (m, 2H), 6.62 (m, 1H), 5.21 (d, 1H, $J_{1,2}$ 4.0 Hz, H-1''), 4.57 (m, 2H, H-1', 1H), 4.51 (d, 1H, $J_{1,2}$ 8.0 Hz, H-1), 4.26 (m, 2H, H-4', H-5''), 4.08 (d, 1H, $J_{4,3}$ 3.5 Hz, H-4''), 4.01 (m, 3H, H-3'', H-6a, H-6b), 3.93 (dd, 1H, $J_{2,1}$ 3.5, $J_{2,3}$ 10.5 Hz, H-2''), 3.88 (m, 3H, H-3, H-5, H-5''), 3.81 (m, 5H, H-6a', H-6b', H-6a'', H-6b'', 1H), 3.71 (m, 6H, H-2', H-3, 2 x CH₂), 3.62 (m, 3H, H-4, CH₂), 3.47 (m, 2H), 3.41 (dd, 1H, $J_{2,1} \approx J_{2,3}$ 8.0 Hz, H-2), 2.40 (m, 4H), 1.41 (m, 4H); ^{13}C NMR (D_2O , 125 MHz), δ (ppm): 170.5, 170.2, 147.8, 140.9, 139.3, 137.5, 130.8, 130.4, 128.8, 125.7, 125.6, 125.3, 125.3, 125.1, 103.9 (C-1'), 103.2 (C-1), 96.4 (C-1''), 79.8, 78.3, 76.0, 75.7, 75.4, 73.7, 71.8, 70.6, 70.6, 70.3, 70.1, 69.9, 69.7, 69.2, 65.8, 61.9, 61.9, 61.2, 53.7, 39.9, 29.7, 29.4, 23.5, 23.2; ESI-HRMS: m/z : calcd for $\text{C}_{41}\text{H}_{57}\text{N}_3\text{NaO}_{21}$: 950.3377; found: 950.3368.

U_{NSC1}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (129.7 mg, 0.18 mmol) afforded final product **U_{NSC1}** (88.5 mg, 0.10 mmol, 79 %) as a white solid, R_f 0.28 (DCM/MeOH/ H_2O , 7:3:0.5), $[\alpha]_D +57.3$ (c 0.7, MeOH); IR (cm^{-1} , solid): 3384, 2930, 2882, 1645, 1075; ^1H NMR (D_2O , 600 MHz), δ (ppm): 8.46 (d, 0.6H, J 4.8 Hz), 8.36 (d, 0.4H, J 4.8 Hz), 7.81 (m, 0.6H), 7.72 (m, 0.4H), 7.31 (m, 3H), 7.05 (m, 0.4H), 7.01 (m, 0.6H), 6.99 (d, 0.6H, J 7.2 Hz), 6.85 (d, 0.4H, J 7.2 Hz), 6.80 (d, 0.6H, J 7.2 Hz), 6.75 (d, 0.4H, J 7.2 Hz), 5.13 (d, 1H, $J_{1,2}$ 4.2 Hz, H-1''), 4.50 (d, 0.6H, $J_{1,2}$ 7.8 Hz, H-1'), 4.48 (d, 0.4H, J 7.8 Hz), 4.46 (d, 0.6H, J 7.8 Hz, H-1), 4.42 (d, 0.4H, J 7.8 Hz), 4.18 (m, 2H, H-4', H-5''), 4.08 (s, 0.8H), 4.05 (s, 1.20H), 3.98 (m, 4H, H-3'', H-4'', H-6a, H-6b), 3.86 (m, 2H, H-2'', 1H), 3.76 (m, 4H, H-3', H-5, H-5''), 3.73 (m, 4H, H-6a', H-6b', H-6a'', H-6b'', 1H), 3.69 (m, 6H, H-2', H-3, 2 x CH₂), 3.61 (m, 3H, H-4, CH₂), 3.55 (m, 1H), 3.52 (m, 3H), 3.34 (dd, 0.6H, $J_{2,1}$ 7.8, $J_{4,3}$ 9.0 Hz, H-2), 3.29 (dd, 0.4H, $J_{2,1}$ 7.8, $J_{4,3}$ 9.0 Hz, H-2), 3.04 (dd, 1.2H, J 6.6, J 6.6 Hz), 2.98 (dd, 0.8H, J 6.6, J 6.6 Hz); ^{13}C NMR (D_2O , 125 MHz), δ (ppm): 175.1, 171.7, 171.2, 164.4-114.6 (aromatic Cs), 103.7 (C-1'), 102.9 (C-1), 96.3 (C-1''), 79.5, 78.1, 75.9, 75.6, 75.3, 73.6, 71.7, 70.4, 70.4, 70.3, 70.2, 69.9, 69.7, 69.6, 69.1, 65.7, 61.8, 61.8, 61.0, 51.9, 50.7, 50.4, 48.5, 40.3, 39.8, 39.4, 36.4, 35.4; ESI-HRMS: m/z : calcd for $\text{C}_{39}\text{H}_{56}\text{FN}_3\text{NaO}_{19}$: 912.3384; found: 912.3379.

U_{NSC2}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (116.9 mg, 0.16 mmol) afforded final product **U_{NSC2}** (69.0 mg, 0.08 mmol, 78 %) as a white solid, R_f 0.28 (DCM/MeOH/ H_2O , 7:3:0.5), $[\alpha]_D +57.8$ (c 0.5, MeOH); IR (cm^{-1} , solid): 3399, 2939, 2872, 1640, 1075; ^1H NMR (D_2O , 600 MHz), δ (ppm): 8.47 (d, 0.6H, J 4.8 Hz), 8.41 (d, 0.4H, J 4.8 Hz), 7.80 (m, 1H), 7.33 (m, 2H), 5.13 (d, 1H, $J_{1,2}$ 3.6 Hz, H-1''), 4.50 (d, 1H, $J_{1,2}$ 7.8 Hz, H-1'), 4.49 (d, 0.6H, $J_{1,2}$ 8.4 Hz, H-1), 4.47 (d, 0.4H, $J_{1,2}$ 8.4 Hz, H-1), 4.18 (m, 2H, H-4', H-5''), 3.96 (m, 6H, H-3'', H-4'', H-6a, H-6b, CH₂), 3.85 (dd, 1H, $J_{2,1}$ 3.6, $J_{2,3}$ 10.0 Hz, H-2''), 3.82 (m, 3H, H-3', H-5, H-5''), 3.76 (m, 4H, H-6a', H-6b', H-6a'', H-6b'', 1H), 3.72 (m, 6H, H-2', H-3, 2 x CH₂), 3.62 (m, 5H, H-4, 2 x CH₂), 3.57 (m, 1H), 3.41 (m, 2H), 3.33 (m, 1H, H-2), 3.06 (dd, 1.2H J 6.6, J 6.6 Hz), 2.99 (dd, 0.8H J 6.6, J 6.6 Hz),

2.26 (d, 0.8H, *J* 7.8 Hz), 1.97 (d, 1.2H, *J* 7.8 Hz), 1.96 (m, 0.4H), 1.89 (m, 0.6H), 1.61 (m, 2H), 1.45 (m, 4H), 1.02 (m, 0.8H), 0.87 (m, 1.2H); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 177.9, 177.8, 172.1, 171.8, 159.0, 158.6, 149.6, 149.2, 139.4, 139.1, 125.8, 125.3, 123.7, 123.4, 103.9 (C-1'), 103.1 (C-1), 96.4 (C-1''), 79.6, 78.2, 76.0, 75.7, 75.4, 73.8, 71.8, 70.6, 70.5, 70.4, 71.3, 70.1, 69.8, 69.8, 69.2, 65.8, 61.9, 61.9, 61.1, 51.9, 50.7, 50.4, 39.9, 39.6, 38.9, 37.2, 36.7, 36.6, 35.7, 32.9, 32.9, 25.4, 25.4, 25.3; ESI-HRMS: *m/z*: calcd for C₃₈H₆₁N₃NaO₁₉: 886.3791; found: 886.3788.

UN_{5C3}. Ugi coupling and subsequent deacetylation and enzymatic α-galactosylation of lactose-derived isocyanide **6** (121.5 mg, 0.17 mmol) afforded final product **UN_{5C3}** (77.1 mg, 0.087 mmol, 73 %) as a white solid, *R_f* 0.32 (DCM/MeOH/H₂O, 7:3:0.5), [α]_D +54.2 (*c* 0.9, MeOH); IR (cm⁻¹, solid): 3396, 2926, 2886, 1639, 1075; ¹H NMR (D₂O, 600 MHz), δ (ppm): 8.45 (d, 0.6H, *J* 4.8 Hz), 8.36 (d, 0.4H, *J* 4.8 Hz), 7.80 (m, 0.6H), 7.71 (m, 0.4H), 7.36 (m, 0.6H), 7.28 (m, 1H), 7.23 (d, 0.4H, *J* 7.8 Hz), 7.18 (d, 0.8H, *J* 7.8 Hz), 7.15 (d, 1.2H, *J* 7.8 Hz), 6.98 (d, 0.8H, *J* 7.8 Hz), 6.91 (d, 1.2H, *J* 7.8 Hz), 5.13 (d, 1H, *J*_{1,2} 4.2 Hz, H-1''), 4.49 (d, 0.6H, *J*_{1,2} 7.8 Hz, H-1'), 4.48 (d, 0.4H, *J*_{1,2} 7.8 Hz, H-1'), 4.45 (d, 0.6H, *J*_{1,2} 8.4 Hz, H-1), 4.40 (d, 0.4H, *J*_{1,2} 8.4 Hz, H-1), 4.17 (m, 2H, H-4', H-5''), 4.03 (s, 2H), 3.94 (m, 4H, H-3'', H-4'', H-6a, H-6b), 3.85 (dd, 1H, *J*_{2,1} 4.2, *J*_{2,3} 10.8 Hz, H-2''), 3.78 (m, 3H, H-3', H-5, H-5'), 3.74 (m, 6H, H-6a', H-6b', H-6a'', H-6b'', CH₂), 3.68 (m, 6H, H-2', H-3, 2 x CH₂), 3.55 (m, 4H), 3.51 (m, 1H), 3.39 (m, 3H, H-2, CH₂), 3.01 (dd, 1.2H, *J* 6.6, *J* 6.6 Hz), 2.97 (dd, 0.8H, *J* 6.6, *J* 6.6 Hz), 2.31 (s, 1.2H), 2.28 (s, 1.8H); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 177.5, 177.5, 173.5, 172.9, 160.4, 160.0, 151.2, 150.8, 149.0, 140.6, 139.8, 139.7, 133.8, 133.5, 131.9, 131.9, 131.8, 131.7, 131.6, 131.5, 127.2, 126.9, 125.3, 124.9, 105.4 (C-1'), 104.6 (C-1), 97.9 (C-1''), 81.2, 79.8, 77.6, 77.3, 76.9, 75.3, 75.3, 73.4, 72.1, 72.1, 71.9, 71.9, 71.7, 71.4, 71.2, 70.8, 67.4, 63.5, 63.5, 62.7, 53.7, 52.4, 52.2, 50.2, 42.2, 41.5, 41.1, 38.1, 37.1, 22.7; ESI-HRMS: *m/z*: calcd for C₄₀H₅₉N₃NaO₁₉: 908.3635; found: 908.3630.

UN_{5C4}. Ugi coupling and subsequent deacetylation and enzymatic α-galactosylation of lactose-derived isocyanide **6** (150.8 mg, 0.21 mmol) afforded final product **UN_{5C4}** (99.2 mg, 0.11 mmol, 57%) as a white solid, *R_f* 0.30 (DCM/MeOH/H₂O, 7:3:0.5), [α]_D +57.8 (*c* 0.8, MeOH); IR (cm⁻¹, solid): 3376, 2930, 2877, 1663, 1075; ¹H NMR (D₂O, 600 MHz), δ (ppm): 8.44 (m, 1H), 7.79 (m, 1H), 7.32 (m, 2H), 5.37 (dd, 0.5H, *J* 6.6, *J* 6.6 Hz), 5.13 (d, 1H, *J*_{1,2} 4.2 Hz, H-1''), 5.09 (dd, 0.5H, *J* 6.6, *J* 6.6 Hz), 4.49 (m, 2H, H-1', H-1), 4.19 (m, 2H, H-4', H-5''), 4.09 (m, 1H), 4.04 (s, 2H), 4.01 (d, 1H, *J*_{4,3} 3.6 Hz, H-4''), 3.95 (m, 2H, H-6a, H-6b), 3.85 (m, 2H, H-3'', H-2''), 3.79 (m, 3H, H-3', H-5, H-5'), 3.74 (m, 4H, H-6a', H-6b', H-6a'', H-6b''), 3.71 (m, 6H, H-2', H-3, 2 x CH₂), 3.64 (m, 5H, H-4, 2 x CH₂), 3.57 (m, 1H), 3.41 (m, 2H), 3.34 (m, 1H, H-2), 2.00 (m, 2H), 1.63 (s, 1.5H), 1.51 (s, 1.5H), 0.90 (m, 3H); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 179.8, 179.5, 173.5, 173.2, 160.5, 160.1, 151.2, 150.7, 140.8, 140.7, 137.4, 136.7, 131.6, 131.1, 127.1, 127.0, 125.2, 125.0, 105.4 (C-1'), 104.7 (C-1), 97.9 (C-1''), 81.2, 79.8, 77.6, 77.3, 76.9, 75.3, 73.4, 72.1, 72.0, 71.9, 71.7, 71.4, 71.4, 70.8, 67.4, 63.5, 63.5, 62.7, 54.5, 53.3, 50.9, 49.1, 41.5, 41.5, 38.1, 36.9, 22.9, 15.5, 15.1, 14.9; ESI-HRMS: *m/z*: calcd for C₃₇H₅₉N₃NaO₁₉: 872.3635; found: 872.3631.

UN_{5C5}. Ugi coupling and subsequent deacetylation and enzymatic α-galactosylation of lactose-derived isocyanide **6** (125.0 mg, 0.17 mmol) afforded final product **UN_{5C5}** (87.1 mg, 0.097 mmol, 57%) as a white solid, *R_f* 0.32 (DCM/MeOH/H₂O, 7:3:0.5), [α]_D +54.4 (*c* 0.5, MeOH); IR (cm⁻¹, state): 3394,

2924, 2886, 1633, 1075; ¹H NMR (D₂O, 600 MHz), δ (ppm): 8.49 (d, 0.3H, *J* 4.8 Hz), 8.33 (dd, 0.3H, *J* 1.2, *J* 8.4 Hz), 8.27 (dd, 0.7H, *J* 1.2, *J* 8.4 Hz), 8.17 (d, 0.7H, *J* 4.8 Hz), 8.08 (m, 0.3H), 7.84 (m, 0.3H), 7.72 (m, 0.7H), 7.69 (dd, 0.3H, *J* 8.4, *J* 8.4 Hz), 7.66 (m, 0.7), 7.63 (m, 0.7H), 7.60 (dd, 0.7H, *J* 8.4, *J* 8.4 Hz), 7.47 (m, 0.3H), 7.42 (d, 0.3H, *J* 7.8 Hz), 7.35 (m, 0.3H), 7.26 (m, 0.7H), 7.17 (d, 0.7H, *J* 7.8 Hz), 5.13 (d, 1H, *J*_{1,2} 4.2 Hz, H-1''), 4.50 (d, 0.3H, *J*_{1,2} 7.8 Hz, H-1'), 4.49 (d, 0.7H, *J*_{1,2} 7.8 Hz, H-1'), 4.48 (d, 0.7H, *J*_{1,2} 8.4 Hz, H-1), 4.44 (d, 0.3H, *J*_{1,2} 8.4 Hz, H-1), 4.33 (s, 2H), 4.18 (m, 2H, H-4', H-5''), 4.02 (d, 1H, *J*_{4,3} 3.0 Hz, H-4''), 3.94 (m, 3H, H-3'', H-6a, H-6b), 3.86 (m, 2H, H-2, 1H), 3.80 (m, 3H, H-3', H-5, H-5''), 3.76 (m, 6H, H-6a', H-6b', H-6a'', H-6b'', CH₂), 3.69 (m, 4H, H-2', H-3, CH₂), 3.62 (m, 3H, H-4, CH₂), 3.54 (m, 3H), 3.31 (m, 1H, H-2), 3.15 (dd, 0.6H, *J* 6.6, *J* 6.6 Hz), 2.94 (dd, 1.4H, *J* 6.6, *J* 6.6 Hz); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 172.9, 172.8, 171.2, 170.9, 158.9, 157.8, 149.4, 149.3, 148.6, 148.5, 139.1, 139.1, 136.8, 135.9, 133.7, 133.6, 131.4, 131.0, 125.9, 125.8, 125.6, 125.4, 123.6, 123.5, 123.5, 122.6, 122.2, 103.8 (C-1'), 103.0 (C-1), 96.3 (C-1''), 79.6, 79.5, 78.1, 75.9, 75.6, 75.3, 73.7, 71.7, 70.5, 70.4, 70.3, 70.2, 70.0, 69.8, 69.7, 69.5, 69.1, 65.7, 61.9, 69.8, 61.0, 53.1, 52.2, 50.0, 48.3, 39.9, 39.8, 36.2, 35.3; ESI-HRMS: *m/z*: calcd for C₃₈H₅₄N₄NaO₂₁: 925.3173; found: 925.3165.

UN_{6C1}. Ugi coupling and subsequent deacetylation and enzymatic α-galactosylation of lactose-derived isocyanide **6** (123.4 mg, 0.17 mmol) afforded final product **UN_{6C1}** (40.9 mg, 0.046 mmol, 60 %) as a white solid, *R_f* 0.36 (DCM/MeOH/H₂O, 7:3:0.5), [α]_D +52.5 (*c* 0.6, MeOH); IR (cm⁻¹, solid): 3370, 2930, 2532, 1647; ¹H NMR (D₂O, 500 MHz), δ (ppm): 7.25 (m, 1H), 7.20 (d, *J* 9.0 Hz, 2H), 7.08 (m, 1H), 6.96 (d, *J* 9.0 Hz, 2H), 6.82 (m, 1H), 6.75 (m, 1H), 5.12 (d, *J*_{1,2} 4.0 Hz, H-1''), 4.48 (d, *J*_{1,2} 8.0 Hz, H-1''), 4.42 (d, *J*_{1,2} 8.0 Hz, H-1), 4.33 (s, NHCH₂), 4.16 (m, H-5'', H-4'), 4.00 (d, *J*_{4,3} 3.5 Hz, H-4''), 3.93 (m, H-3'', H-6a, H-6b), 3.84 (dd, *J*_{2,1} 3.5, *J*_{2,3} 10.0 Hz, H-2''), 3.79 (s, 3H), 3.76 (m, H-3', H-5, H-5''), 3.69 (m, H-6a', H-6b', H-6a'', H-6b'', 1H), 3.65 (m, H-2', H-3, CH₂, 1H), 3.55 (m, H-4, 2 x CH₂), 3.35 (m, CH₂), 3.29 (dd, *J*_{2,1} 8.0, *J*_{2,3} 9.5 Hz, H-2); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 175.3, 171.3, 164-114 (aromatics Cs), 103.8 (C-1'), 103.1 (C-1), 96.4 (C-1''), 79.6, 78.2, 76.0, 75.7, 75.4, 73.7, 71.8, 70.6, 70.5, 70.3, 70.1, 69.8, 69.8, 69.2, 65.8, 61.9, 61.9, 61.1, 56.6, 53.9, 41.2, 39.9; ESI-HRMS: *m/z*: calcd for C₃₉H₅₅FN₂NaO₂₀: 913.3224; found: 913.3218.

UN_{6C2}. Ugi coupling and subsequent deacetylation and enzymatic α-galactosylation of lactose-derived isocyanide **6** (120.7 mg, 0.17 mmol) afforded final product **UN_{6C2}** (41.5 mg, 0.048 mmol, 57 %) as a white solid, *R_f* 0.40 (DCM/MeOH/H₂O, 7:3:0.5), [α]_D +20.4 (*c* 1.2, MeOH); IR (cm⁻¹, solid): 3365, 2937, 2869, 2491, 1652; ¹H NMR (D₂O, 500 MHz), δ (ppm): 7.25 (d, 2H, *J* 8.9 Hz), 6.99 (d, 2H, *J* 8.9 Hz), 5.11 (d, 1H, *J*_{1,2} 3.9 Hz, H-1''), 4.47 (d, 1H, *J*_{1,2} 7.9 Hz, H-1'), 4.42 (d, 1H, *J*_{1,2} 8.0 Hz, H-1), 4.33 (d, 1H, *J*_{1,2} 16.1 Hz), 4.30 (d, 1H, *J* 16.1 Hz), 4.15 (m, 2H, H-4', H-5''), 3.98 (d, 1H, *J*_{4,3} 3.7 Hz, H-4''), 3.94 (m, 3H, H-3'', H-6a, H-6b), 3.81 (dd, 1H, *J*_{2,1} 3.9, *J*_{2,3} 10.3 Hz, H-2''), 3.81 (s, 3H), 3.74 (m, 3H, H-3', H-5, H-5'), 3.67 (m, 4H, H-6a', H-6b', H-6a'', H-6b''), 3.60 (m, 6H, H-2', H-3, 2 x CH₂), 3.54 (m, 3H, H-4, CH₂), 3.36 (m, 2H), 3.29 (dd, 1H, *J*_{2,1} 8.0, *J*_{2,3} 9.3 Hz, H-2), 2.17 (d, 2H, *J* 7.5 Hz), 2.05 (m, 1H), 1.64 (m, 2H), 1.42 (m, 4H), 0.96 (m, 2H); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 177.9, 171.5, 159.7, 136.1, 130.0, 130.0, 115.9, 115.9, 103.9 (C-1'), 103.1 (C-1), 96.4 (C-1''), 79.6, 78.2, 76.0, 75.7, 75.4, 73.7, 71.8, 70.6, 70.5, 70.3, 70.1, 69.8, 69.8, 69.2, 65.8, 61.9, 61.9, 61.1, 56.6, 53.7, 40.2,

39.9, 37.6, 32.8, 32.8, 25.2, 25.2; ESI-HRMS: m/z : calcd for $C_{38}H_{60}N_2NaO_{20}$: 887.3632; found: 887.3626.

U_{N6C3}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (130.6 mg, 0.18 mmol) afforded final product **U_{N6C3}** (84.2 mg, 0.095 mmol, 53%) as a white solid, R_f 0.40 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D^{25} +57.1$ (c 0.4, MeOH); IR (cm⁻¹, solid): 3347, 2921, 1644; ¹H NMR (D₂O, 500 MHz), δ (ppm): 7.23 (d, 2H, J 9.0 Hz), 7.12 (d, 2H, J 8.0 Hz), 6.97 (d, 2H, J 9.0 Hz), 6.93 (d, 2H, J 8.0 Hz), 5.21 (d, 1H, $J_{1,2}$ 4.0 Hz, H-1''), 4.57 (d, 1H, $J_{1,2}$ 8.0 Hz, H-1'), 4.49 (d, 1H, $J_{1,2}$ 7.5 Hz, H-1), 4.38 (s, 2H), 4.26 (m, 2H, H-4', H-5''), 4.08 (d, 1H, $J_{4,3}$ 3.0 Hz, H-4''), 4.02 (m, 3H, H-3'', H-6a, H-6b), 3.93 (dd, 1H, $J_{2,1}$ 3.5, $J_{2,3}$ 10.0 Hz, H-2''), 3.87 (m, 3H, H-3', H-5, H-5'), 3.83 (s, 3H), 3.79 (m, 4H, H-6a', H-6b', H-6a'', H-6b''), 3.72 (m, 6H, H-2', H-3, 2 x CH₂), 3.62 (m, 3H, H-4, CH₂), 3.52 (s, 2H), 3.44 (m, 2H), 3.38 (dd, 1H, $J_{2,1} \approx J_{2,3}$ 8.5 Hz, H-2), 2.29 (s, 3H); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 175.8, 171.3, 159.8, 137.8, 135.8, 132.6, 130.1, 130.1, 130.0, 130.0, 129.9, 129.9, 115.8, 115.8, 103.9 (C-1'), 103.1 (C-1), 96.4 (C-1''), 79.7, 78.2, 76.0, 75.7, 75.4, 73.7, 71.8, 70.6, 70.5, 70.3, 70.1, 69.8, 69.2, 65.8, 61.9, 61.9, 61.1, 56.5, 56.5, 53.9, 40.9, 39.9, 21.1; ESI-HRMS: m/z : calcd for $C_{40}H_{58}N_2NaO_{20}$: 909.3475; found: 909.3569.

U_{N6C4}. Ugi coupling and subsequent deacetylation and enzymatic α -galactosylation of lactose-derived isocyanide **6** (124.0 mg, 0.17 mmol) afforded final product **U_{N6C4}** (80.0 mg, 0.094 mmol, 55%) as a white solid, R_f 0.34 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D^{25} +61.7$ (c 0.5, MeOH); IR (cm⁻¹, solid): 3352, 2930, 1662; ¹H NMR (D₂O, 500 MHz), δ (ppm): 7.28 (d, 2H, J 9.0 Hz), 7.04 (d, 2H, J 9.0 Hz), 5.75 (m, 1H), 5.21 (d, 1H, $J_{1,2}$ 4.0 Hz, H-1''), 4.58 (d, 1H, $J_{1,2}$ 7.5 Hz, H-1'), 4.53 (d, 1H, $J_{1,2}$ 8.0 Hz, H-1'), 4.51 (s, 2H), 4.26 (m, 2H, H-4', H-5''), 4.08 (d, 1H, $J_{4,3}$ 3.5 Hz, H-4''), 4.03 (m, 3H, H-3'', H-6a, H-6b), 3.93 (d, 1H, $J_{2,1}$ 3.5, $J_{2,3}$ 10.0 Hz, H-2''), 3.88 (s, 3H), 3.84 (m, 3H, H-3', H-5, H-5'), 3.80 (m, 4H, H-6a', H-6b', H-6a'', H-6b''), 3.71 (m, 6H, H-2', H-3, 2 x CH₂), 3.63 (m, 3H, H-4, CH₂), 3.45 (m, 2H), 3.39 (d, 1H, $J_{2,1} \approx J_{2,3}$ 8.5 Hz, H-2''), 1.95 (m, 2H), 1.62 (s, 3H), 0.76 (s, 3H); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 171.4, 171.4, 159.0, 130.3, 129.4, 129.4, 115.5, 103.9 (C-1'), 103.1 (C-1), 96.4 (C-1''), 79.6, 78.2, 76.0, 75.7, 75.4, 73.7, 71.8, 70.6, 70.5, 70.3, 70.1, 69.8, 69.8, 69.8, 69.2, 65.8, 61.9, 61.9, 61.1, 56.5, 56.5, 39.9, 21.4, 14.1, 13.0; ESI-HRMS: m/z : calcd for $C_{37}H_{58}N_2NaO_{20}$: 873.3475; found: 873.3469.

U_{N6C5}. Ugi coupling and subsequent Zemplén deacetylation of trisaccharide isocyanide **7** (69.3 mg, 0.068 mmol) afforded **U_{N6C5}** (46.7 mg, 0.052 mmol, 76%) as a white solid, R_f 0.36 (DCM/MeOH/H₂O, 7:3:0.5), $[\alpha]_D^{25} +54.0$ (c 0.4, MeOH); IR (cm⁻¹, solid): 3349, 2931, 1636; ¹H NMR (D₂O, 600 MHz), δ (ppm): 8.18 (s, 1H), 8.13 (d, 1H, J 8.4 Hz), 7.71 (d, 1H, J 7.8 Hz), 7.47 (dd, 1H, J 7.8, 7.8 Hz), 7.18 (d, 2H, J 8.4 Hz), 6.82 (d, 2H, J 8.4 Hz), 5.13 (d, 1H, J 3.6 Hz, H-1''), 4.64 (s, 2H, NHCH₂), 4.50 (d, 1H, J 7.8 Hz, H-1'), 4.45 (d, 1H, J 7.8 Hz, H-1), 4.18 (m, 2H, H-5'', H-4'), 3.96 (m, 4H, H-4'', H-3'', H-6a, H-6b), 3.85 (dd, $J_{2,1}$ 3.6, $J_{2,3}$ 10.2 Hz, H-2''), 3.79 (m, 3H, H-3', H-5, H-5'), 3.72 (m, 5H, H-6a', H-6b', H-6a'', H-6b''), 3.69 (s, 3H), 3.67 (m, 3H, H-2', H-3, 1H), 3.62 (m, 4H, H-4, CH₂, 1H), 3.55 (m, 1H), 3.44 (m, 2H), 3.31 (dd, $J_{2,1} \approx J_{2,3}$ 7.8 Hz, H-2); ¹³C NMR (D₂O, 125 MHz), δ (ppm): 171.9, 171.1, 159.1, 148.2, 136.9, 136.1, 135.4, 130.7, 130.0, 130.0, 125.9, 124.3, 115.7, 115.7, 103.9 (C-1''), 103.1 (C-1), 96.4 (C-1''), 79.7, 78.2, 76.0, 75.2, 75.4, 73.7, 71.8, 70.6, 70.5, 70.3, 70.1, 69.8, 69.8, 69.2, 65.8, 61.9, 61.9, 61.1, 56.5, 54.2, 40.0; ESI-HRMS: m/z : calcd for $C_{38}H_{53}N_3NaO_{22}$: 926.3013; found: 926.3008.

Evaluation of binding activity by mass spectrometry

For the ESI-MS assay, complete details of the experimental methodology and data analysis are described elsewhere.⁴² The TcdA-A2 fragment (A2, MW 29 580 Da) and TcdB-B3C fragment (B3C, MW 30 240 Da) were expressed in *E. coli* and purified as previously described.^{43, 44} Apparent association constants ($K_{a,app}$) for the fragments TcdA-A2 and TcdB-B3C binding to the library of thirty compounds were evaluated using the direct ESI-MS assay. Prior to analysis, the TcdA-A2 and TcdB-B3C solutions were diluted with 50 mM ammonium acetate (pH 7.2) and concentrated using Amicon Ultra-4 centrifugal filters with a molecular weight cut-off of 10,000 Da (Millipore). The concentrations of the TcdA-A2 and TcdB-B3C solutions were measured by UV absorption. Each ESI solution was prepared from stock solutions of protein (TcdA-A2 and TcdB-B3C) and one of carbohydrate ligands. Lysozyme and α -lactalbumin were used as reference proteins (P_{ref}) to distinguish specific from nonspecific ligand binding with TcdA-A2 and TcdB-B3C, respectively, during the ESI-MS measurements. Electrospray ionization mass spectrometry (ESI-MS) measurements were conducted using an Apex-Qe 9.4 T Fourier transform ion cyclotron resonance mass spectrometer (FT-ICR MS) (Bruker, Billerica, MA) equipped with an external Nano-ESI source. NanoESI-MS was carried out with NanoMate 100 (Advion Bio-Sciences, Ithaca, NY). Data acquisition and analysis were performed using ApexControl, version 4.0 (Bruker Daltonics). A minimum of 25 transients was used for each acquisition.

Conformational analysis

We conducted MD simulations using Amber 11 with the General Amber Force Field (gaff) and partial charges assigned by the *sqm* program using the AM1-BCC charge method. Molecules were placed in a rectangular box to allow at least 12 Å distance from any atom to the box border and the box was saturated with water. After minimization (first, 1000 steps of steepest descent then 1000 steps with the conjugate gradients with restrained solute (500 kcal mol⁻¹Å⁻²) the system was heated to 300 K with weak restrains to solute (10 kcal mol⁻¹Å⁻²) and equilibrated for 30 ps with controlled pressure and temperature. Production runs were performed at 1 atm, 300 K using the Langevin heat bath with 1 ps⁻¹ collision frequency. Non-bonded interactions were evaluated with a 8 Å cut off and the SHAKE constraint system for bonds to hydrogen was enabled. Long-range electrostatics were treated with particle-mesh Ewald (PME) periodic boundary conditions. Trajectories were saved every 2 ps. For all trajectories, distances of interest were extracted, expected NOE effects were summed up as reciprocal six power of the distance (r^{-6}) and normalized assuming the reference distance H-1(Glc)—H-5(Glc) to be 100%.

Construction of combinatorial library of virtual compounds

Library enumeration and generation of 3D structures was accomplished using in-house software (see description in Supplementary Information, also available from authors upon request) based on Open Babel and Pybel modules in Python. Each compound was generated in the form of two alternative isomers differing in the configuration of the terminal amide bond, designated as "cis" and "trans" according to the conventional definition for peptide bond conformations, that is, ignoring substituent at the nitrogen atom in a peptoid moiety. All structures were subjected to energy minimization using the

MMFF94s force field and steepest gradient (500 steps) followed by conjugate gradient (until convergence or 5000 steps). In order to avoid folding and ring distortions during minimization, positional constraints were applied to the trisaccharide atoms, linker and peptoid scaffold. The protein structure was prepared from the crystal structure (pdb entry: 2G7C) by removing all low molecular weight species and the protein chain B. Protons were added to all hetero atoms of the remaining protein chain A using MGLTools followed by generating a pdbqt file of the receptor. Automatic molecular docking was performed on multi-CPU cluster computers using Autodock Vina²⁸ with an exhaustiveness set at 64. The grid box dimensions were 20×20×20 Å and it was centered on the coordinates (x, y, z)=(25.45, 15.1, 5.9) Å. Each ligand was resubmitted several times until at least one pose was obtained, in which the position of the trisaccharide fragment matched the position of the trisaccharide in the crystal structure with a RMSD less than 1.5 Å.

In silico ranking of ligands

Preparation of molecular structures was conducted as described for preparation of the virtual library except the torsional constraints for peptoid amide bond were removed in order to increase the docking success rate. Ten automated docking sessions performed with Autodock Vina (different random seeds, exhaustiveness set at 64) yielded from 2 to 15 poses per compound, in which the position of the trisaccharide matched that found in the crystal structure with RMSD lower than 0.5 Å. Crystal structure determination of the TcdA-A2 complex with U_{NSC2} TcdA-A2 was expressed, purified and crystallized as previously described.^{26,43} U_{NSC2} (5 μL X 50 mM) was added to 10 μL of a 1.5X strength precipitant solution to generate 15 μL of precipitant solution containing 16.7 mM U_{NSC2} (Solution A). Crystals (~0.4 x 0.01 x 0.01 mm) were soaked in Solution A for 60 minutes before flash freezing under nitrogen gas (100 K) and storage in liquid nitrogen. The frozen crystal was mounted at the Canadian Macromolecular Crystallography Facility Beamline 08B1-1, where diffraction data (400 images X 0.5° rotation) were measured using a Marmosaic MX300 CCD X-ray detector. Data were processed and scaled using XDS and XSCALE (40-1.7 Å, R_{sym} = 0.057, I/σ = 13.9).⁴⁵ Crystals were isomorphous to the TcdA-A2 trisaccharide complex (Space group P2₁, a= 38.89, b=65.69, c=132.85, β=100.75°),²⁶ and the structure was refined using REFMAC (R_{work}=0.184, R_{free}=0.215).⁴⁶ Electron density maps were calculated using FFT and COOT, and model building was performed using COOT.⁴⁷ Figures 4 and 5 were prepared using PyMOL (Schrödinger LLC).

Acknowledgements

We thank the Alberta Glycomics Centre for financial support, Compute Canada for providing access to WestGrid clusters, and Dr. W. W. Wakarchuk of the National Research Council of Canada for providing cell-lines expressing α-(1-3)-galactosyl transferase and UDP-glucose 4-epimerase used for the synthesis of the trisaccharide. X-ray diffraction data were measured at beamline 08B1-1 of the Canadian Light Source (CLS), which is supported by the Natural Sciences and Engineering Research Council of Canada, the National Research Council Canada, the Canadian Institutes of Health Research, the Province of Saskatchewan, Western Economic Diversification Canada, and the University of Saskatchewan.

Notes and references

- ^a Department of Chemistry, University of Alberta, Edmonton, Canada, Fax: (+1)-780-492-7705, E-mail: dave.bundle@ualberta.ca
- ^b Department of Biological Sciences, University of Calgary, Calgary, Canada.
- 1 J. G. Bartlett, *Clin. Infect. Dis.* 1994, **18**, S265-S272.
- 2 M. Kachrimanidou and N. Malisiovas, *Crit. Rev. Microbiol.*, 2011, **37**, 178-187.
- 3 E. R. Dubberke and M. A. Olsen, *Clin. Infect. Dis.*, 2012, **55 Suppl 2**, S88-92.
- 4 M. C. Hammitt, D. A. Bueschel, A. K. Kee, R. D. Glock, P. Cuneo, D. W. DeYoung, C. Reggiardo, H. T. Trinh and J. G. Songer, *Vet. Microbiol.*, 2008, **127**, 343-352.
- 5 A. Goorhuis, D. Bakker, J. Corver, S. B. Debast, C. Harmanus, D. W. Notermans, A. A. Bergwerff, F. W. Dekker and E. J. Kuijper, *Clin. Infect. Dis.*, 2008, **47**, 1162-1170.
- 6 M. A. Jhung, A. D. Thompson, G. E. Killgore, W. E. Zukowski, G. Songer, M. Warny, S. Johnson, D. N. Gerding, L. C. McDonald, and B. M. Limbago, *Emerging Infect. Dis.*, 2008, **14**, 1039-1045.
- 7 E. J. Kuijper, J. T. van Dissel and M. H. Wilcox, *Curr. Opin. Infect. Dis.*, 2007, **20**, 376-383.
- 8 K. Mullane, *Ther. Adv. Chronic Dis.*, 2014, **5**, 69-84.
- 9 B. Geric, R. J. Carman, M. Rupnik, C. W. Genheimer, S. P. Sambol, D. M. Lysterly, D. N. Gerding and S. Johnson, *J. Infect. Dis.*, 2006, **193**, 1143-1150.
- 10 H. C. Krivan, G. F. Clark, D. F. Smith and T. D. Wilkins, *Infect. Immun.*, 1986, **53**, 573-581.
- 11 X. Y. Wu and R. R. Schmidt, *J. Org. Chem.*, 2004, **69**, 1853-1857.
- 12 (a) A. El-Hawiet, E. N. Kitova, P. I. Kitov, L. Eugenio, K. K. Ng, G. L. Mulvey, T. C. Dingle, A. Szpacenko, G. D. Armstrong and J. S. Klassen, *Glycobiology*, 2011, **21**, 1217-1227. (b) Dingle, T., Wee, S., Mulvey, G. L., Greco, A., Kitova, E. N., Sun, J., Lin, S., *et al* *Glycobiology*, 2008, **18**, 698-706.
- 13 S. Teneberg, I. Lonroth, J. F. T. Lopez, U. Galili, M. O. Halvarsson, J. Angstrom and K. A. Karlsson, *Glycobiology*, 1996, **6**, 599-609.
- 14 K. D. Tucker and T. D. Wilkins, *Infect. Immun.*, 1991, **59**, 73-78.
- 15 I. Just, F. Hofmann, H. Genth and R. Gerhard, *Int. J. Med. Microbiol.*, 2001, **291**, 243-250.
- 16 R. N. Pruitt, M. G. Chambers, K. K. S. Ng, M. D. Ohi and D. B. Lacy, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**, 13467-13472.
- 17 T. Jank, T. Giesemann and K. Aktories, *Glycobiology*, 2007, **17**, 15R-22R. J. Zeiser, I. A. *J. Proteome Res.*, 2013, **12**, 1604-1618.
- 18 I. Just and R. Gerhard, *Rev. Physiol., Biochem., Pharmacol.*, 2004, **152**, 23-47.
- 19 M. Rupnik, *FEMS Microbiol. Rev.*, 2008, **32**, 541-555.
- 20 P. Spigaglia, F. Barbanti and P. Mastrantonio, *J. Antimicrob. Chemother.* 2011, **66**, 2227-2234.
- 21 I. Lowy, D. C. Molrine, B. A. Leav, B. M. Blair, R. Baxter, D. N. Gerding, G. Nichol, W. D. Thomas, M. Leney, S. Sloan, C. A. Hay and D. M. Ambrosino, *N. Engl. J. Med.*, 2010, **362**, 197-205.
- 22 G. S. Tillotson and J. Tillotson, *F1000 Medicine Reports*, 2011, **3**, (1 March 2011).
- 23 K. Weiss, *Int. J. Antimicrob. Agents*, 2009, **33**, 4-7.
- 24 S. J. Abdeen, R. J. Swett and A. L. Feig, *ACS Chem. Biol.*, 2010, **5**, 1097-1103.

- 25 A. W. Puri, P. J. Lupardus, E. Deu, V. E. Albrow, K. C. Garcia, M. Bogyo and A. Shen, *Chemistry & Biology*, 2010, **17**, 1201-1211;
- 26 A. Greco, J. G. S. Ho, S. J. Lin, M. M. Palcic, M. Rupnik and K. K. S. Ng, *Nat. Struct. Mol. Biol.*, 2006, **13**, 460-461.
- 27 N. M. O'Boyle, M. Banck, C. A. James, C. Morley, T. Vandermeersch and G. R Hutchison, *J. Cheminf.* 2011, **3:33**, 1-14.
- 28 O. Trott and A. Olson, *J. Comput. Chem.*, 2010, **31**, 455-461.
- 29 D. H. Joziassse, J. H. Shaper, D. H. Vandeneijnden, A. J. Vantunen and N. L. Shaper, *J. Biolog. Chem.*, 1989, **264**, 14290-14297.
- 30 S. Bernatchez, C. M. Szymanski, N. Ishiyama, J. J. Li, H. C. Jarrell, P. C. Lau, A. M. Berghuis, N. M. Young and W. W. Wakarchuk, *J. Biol. Chem.*, 2005, **280**, 4792-4802.
- 31 P. Reddy and S. Baskaran, *Tetrahedron Lett.*, 2002, **43**, 1919-1922.
- 32 W. Brandt, T. Herberg and L. Wessjohann, *Biopolymers*, 2011, **96**, 651-668.
- 33 D. M. Schnur, Y. H. Yuh and D. R. Dalton, *J. Org. Chem.*, 1989, **54**, 3779-3785.
- 34 N. H. Shah, G. L. Butterfoss, K. Nguyen, B. Yoo, R. Bonneau, D. L. Rabenstein and K. Kirshenbaum, *J. Am. Chem. Soc.*, 2008, **130**, 16622-16632.
- 35 E. N. Kitova, A. El-Hawiet, P. D. Schnier and J. S. Klassen, *J. Am. Soc. Mass. Spectrom.*, 2012, **23**, 431-441.
- 36 P. Strazzolini, A. G. Giumanini and S. Cauci, *Tetrahedron*, 1990, **46**, 1-2.
- 37 J. P. Praly and R. U. Lemieux, *Can. J. Chem.*, 1987, **65**; R. U. Lemieux and K. Bock, *Arch. Biochem. Biophys.*, 1983, **221**, 213-223.
- 38 M. R. Wormald, A. J. Petrescu, Y. L. Pao, A. Glithero, T. Elliott and R. A. Dwek, *Chem. Rev.*, 2002, **102**, 371-386.
- 39 D. Adlercreutz, J. T. Weadge, B. O. Petersen, J. Ø. Duus, N. J. Dovichi and M. M. Palcic, *Carbohydrate Res.*, 2010, **345**, 1384-1388.
- 40 S. Bernatchez, S. Bernatchez, C. M. Szymanski, N. Ishiyama, J. Li, H. C. Jarrell, P. C. Lau, A. M. Berghuis, N. M. Young and W. W. Wakarchuk, *J. Biol. Chem.*, 2005, **280**, 4792-4802.
- 41 F. González Núñez, M. T. Campos Valdes, E. Aruca, R. R. Schmidt, V. V. Bencomo, E. Aruca, M. T. Valdes, R. R. Schmidt and V. V. Bencomo, *J. Carbohydrate Chem.*, 2003, **22**, 1-13.
- 42 J. X. Sun, E. N. Kitova, W. J. Wang and J. S. Klassen, *Anal. Chem.*, 2006, **78**, 3010-3018; W. J. Wang, E. N. Kitova and J. S. Klassen, *Anal. Chem.*, 2003, **75**, 4945-4955.
- 43 J. G. S. Ho, A. Greco, M. Rupnik and K. K. S. Ng, *Proc. Natl. Acad. Sci. U. S. A.*, 2005, **102**, 18373-18378.
- 44 H. Lin, E. N. Kitova, M. A. Johnson, L. Eugenio, K. K. Ng and J. S. Klassen, *J. Am. Soc. Mass. Spectrom.*, 2012, **23**, 2122-2131.
- 45 W. Kabsch, *J. Appl. Cryst.*, 1993, **26**, 795-800.
- 46 G. N. Murshudov, A. A. Vagin and E. J. Dodson, *Acta Crystallogr. D Biol. Crystallogr.*, 1997, **53**, 240-255.
- 47 P. Emsley and K. Cowtan, *Acta Crystallogr. D Biol. Crystallogr.*, 2004, **60**, 2126-2132.

† Electronic Supplementary Information (ESI) available: ^1H and ^{13}C NMR and mass spectra of all compounds. Description of inhouse software for virtual screen is supplied as a txt file. See DOI: 10.1039/b000000x/